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Perfluoroalkyl substances (PFASs), including perfluoroalkyl carboxylates (PFCAs) 
and perfluoroalkyl sulfonates (PFSAs), are persistent amphiphilic chemicals 
many of which are distributed ubiquitously in the environment and can be 
frequently detected in human serum. High doses of certain PFAS cause toxicities 
in animal models. Renal clearance and hepatic accumulation of PFASs can vary 
among different species, between genders in the same species and are also 
influenced by the carbon chain length of the individual PFCAs. In general, PFASs 
with shorter-chain length are eliminated more efficiently through the kidney 
whereas the longer-chain length PFASs tend to accumulate in liver. Although 
there were extensive studies published over the past decade regarding toxicities 
of PFASs in animal models and potential health risks in humans, the molecular 
mechanisms responsible for PFAS’s disposition, such as the roles of specific 
transporters involved, have not been clearly addressed. Absorption, distribution 
and elimination of certain xenobiotics are largely influenced by transporters and 
recently published studies demonstrate that also PFCAs are substrates for 
several transporters. In order to further delineate the pharmacokinetic properties 
of the disposition of PFASs, the involvement of drug transporters expressed in 
liver, intestine and kidney was examined. In the first specific aim, I evaluated the 
hypothesis that drug transporters in the enterohepatic circulation contribute to the 
liver accumulation and long half-lives of long chain PFASs. To address this aim, 
uptake studies with perfluorobutane sulfonate (PFBS), perfluorohexane sulfonate 
(PFHxS) and perfluorooctane sulfonate (PFOS) using cells expressing liver 
	  vi	  
transporters NTCP or OATPs as well as intestinal transporters ASBT, OATPs or 
OSTα/β were performed. The results demonstrated that human and rat NTCP, 
human OATP1B1, OATP1B3, OATP2B1, OSTα/β and rat OATP1A1, OATP1B2, 
OATP2B1, OATP1A5 can transport all three PFSAs, whereas, human ASBT can 
only transport PFOS. In addition, inhibition studies with human MRP2, BCRP and 
BSEP containing Sf9 vesicles suggested that these efflux transporters might be 
involved in the canalicular secretion of PFHxS and/or PFOS in the liver. In the 
second specific aim, I evaluated the hypothesis that the differences of renal 
clearance of PFASs among different species and genders are due to the 
differences of specific transporters expressed in the kidney. To address this aim, 
rat renal transporters OAT1, OAT3 and OATP1A1 were examined for the 
transport of PFBS, PFHxS and PFOS. The results show that the three PFSAs 
are substrates of rat OAT1, OAT3 and OATP1A1. In summary, this dissertation 
reveals that 1) drug transporters expressed in the liver and the intestine and 
involved in the enterohepatic circulation of bile acids contribute to the long half-
lives and the hepatic accumulation of PFHxS and PFOS in humans; 2) drug 
transporters in the liver, the intestine and the kidney contribute to species-, 
gender- and chain length-dependent elimination of PFASs.  
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I. Membrane transport proteins 
 
Cell membranes are lipid barriers surrounding each cell and very few molecules 
can cross the barrier without aid. Membrane transport proteins are proteins 
present in these cellular membranes that mediate the movement of ions, small 
molecules, or macromolecules across the membrane. Transporters can be 
divided, based on energy requirements, into passive or active. Passive 
transporters, or facilitated transporters, mediate transmembrane diffusion of 
solutes along their electrochemical gradient. While on the other hand, active 
transporters transport solutes against their gradient using energy either by using 
ATP directly or in the form of for example a sodium gradient. There are many 
types of membrane transporters, including ion channels, pores, ATPases and so 
on. The two big families of the ATP-binding cassette (ABC) transporters and the 
solute carriers (SLC) are of great importance in pharmacology (Giacomini et al., 
2010).  
  
Transporters play critical roles in the absorption, distribution and excretion of 
drugs and other xenobiotics. When it comes to the disposition of organic 
compounds, mainly the organic anion transporters (OATs) and organic cation 
transporters (OCTs) of the SLC22 superfamily and the organic anion transporting 
polypeptides (OATPs) of the SLCO superfamily are involved. To a lesser extent, 
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members or the SLC10 family can also mediate the influx of xenobiotics beyond 
their roles in bile acid transport. Considering the clinical importance of certain 
transporters with respect to the pharmacokinetics, safety and efficacy profiles of 
drugs, and the potential for drug-drug interactions, the FDA recommends or 
requires that transporters are being evaluated as a routine part of the drug 
development process (www.fda.gov/downloads/ 
drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf) 
(Giacomini et al., 2010).  
  
Fig. 1-1 shows influx and efflux transporters expressed in hepatocytes and 
enterocytes that are important for the work presented in this dissertation. In the 
following, I will provide details regarding the SLC10 and SLCO family focusing on 
their biological and toxicological roles. I will also briefly introduce OSTα-OSTβ, 

















Figure 1-1: Selected SLC and ABC transporters expressed in hepatocytes 
and enterocytes 

































II. Introduction to SLC transporters 
To date, 52 human SLC families with over 300 members have been identified. 
The HUGO Gene Nomenclature Committee (HGNC) website lists all of these 
genes (http://www.genenames.org/genefamilies/slc). At least a 20% amino acid 
identity is required for transporters to be assigned into the same family with a few 
exceptions. For instance, the SLC51 family consists of SLC51A and SLC51B, 
which share no sequence identity but encode the two subunits for the same 
transporter, OSTα-OSTβ. The SLC21 family is now named SLCO, made to 
accommodate a unique species-independent classification system (Hagenbuch 
and Stieger, 2013). In addition to humans, SLCs have been identified in many 
other species. Orthologues of human genes in other species usually use the 
same designation as the human gene (Hediger et al., 2013). 
 
In this part of the introduction, I will focus on the biological, pharmacological and 
pharmaceutical perspectives of some members of the SLC10, SLCO, SLC51 and 
SLC22 families. 
 
A. The SLC10 family 
1) Overview 
The SLC10 family was known as the “sodium bile salt cotransporting family” 
because two of its members are bile salt transporters. It is composed of seven 
members and three of them, including the Na+/taurocholate cotransporting 
polypeptide (NTCP; SLCO10A1), the apical sodium-dependent bile salt 
	  5	  
transporter (ASBT; SLCO10A2) and the sodium-dependent organic anion 
transporter (SOAT; SLCO10A6) have been functionally characterized (Claro da 
Silva et al., 2013).  They utilize the out-to-in sodium gradient to mediate the co-
transport of substrates into the cells. The major role of NTCP and ASBT is to 
facilitate the influx of bile acids in the liver and intestine to ensure the 
enterohepatic circulation of bile acids as digestive helpers and to ensure their 
uptake in other organs as signaling molecules. Besides bile acids, steroidal 
hormones and certain xenobiotics are also substrates of SLC10 members. 
Instead of transporting classic bile acids, SOAT transports sulfated bile acids and 
steroid hormones (Claro da Silva et al., 2013). 
 
2) NTCP 
Rat and human NTCP were cloned in 1991 and 1994 (Hagenbuch et al., 1991; 
Hagenbuch and Meier, 1994), respectively, and have been extensively studied 
since then. NTCP orthologs in humans and rodents have 77% amino acid 
sequence identity. NTCP is expressed on the basolateral membrane of 
hepatocytes (Fig 1-1) to mediate the influx of mainly conjugated bile salts from 
the blood stream. Other substrates of NTCP include steroidal hormones such as 
estrone-3-sulfate and dehydroepiandrosterone sulfate (DHEAS), and a variety of 
xenobiotics such as bromosulfophthalein (BSP) and rosuvastatin (Stieger, 2011).  
 
Expression of NTCP is regulated at both transcriptional and post-transcriptional 
levels. Due to the detergent properties of bile acids, their levels in the circulation 
and inside of cells are tightly regulated. In hepatocytes, high levels of bile acids 
	  6	  
activate the nuclear receptor FXR, which down-regulates the expression of bile 
acid influx transporters (NTCP, ASBT and OATP1B1) via activation of SHP which 
leads to inhibition of HNF1α and the rate-limiting enzymes for bile acid synthesis 
(CYP7A1 and CYP27A1) (Eloranta and Kullak-Ublick, 2008). On the other hand, 
FXR activation up-regulates the expression of detoxifying enzymes and bile acid 
efflux transporters (Matsubara et al., 2013). OATP1B1 is a direct target of FXR, 
and FXR ligands increase OATP1B1 mRNA (Meyer Zu Schwabedissen et al., 
2010). Besides FXR, other nuclear receptors, transcription factors as well as 
hormones also participate in the regulation of NTCP and ASBT. Furthermore, on 
the post-transcriptional level, mechanisms such as ubiquitination and protein 
kinase C-dependent phosphorylation are involved in NTCP and ASBT regulation 
(Claro da Silva et al., 2013). In addition to functioning as a transporter, NTCP is a 
receptor for hepatitis B and D virus, opening new opportunities for developing 
anti-HBV interventions (Yan et al., 2012; Yan et al., 2015). 
 
3) ASBT 
ASBT is localized at the apical membrane of the distal ileum (Fig 1-1), of 
cholangiocytes and of the renal proximal tubules (Dawson, 2011; Claro da Silva 
et al., 2013). The presence of ASBT in the distal ileum enables the circulation of 
bile acids between the liver and intestine, known as enterohepatic circulation. 
This enterohepatic circulation largely depends on the bile acid transporters NTCP 
the bile salt export pump (BSEP) and ASBT (Roberts et al., 2002). It relies on 
biliary secretion and intestinal reabsorption and is also observed for several 
solutes and certain drugs (Gao et al., 2014). As a consequence of the 
	  7	  
enterohepatic circulation, the apparent half-life of a drug or other xenobiotics can 
be increased significantly. In the kidney, ASBT serves as a salvage transporter to 
prevent the loss of bile acids from the glomerular filtration. Due to the efficient 
recycling from small intestine and kidney, less than 10% of bile acids are 
excreted from the body every day. The expression of ASBT in the biliary tract 
together with bile acid transporters in hepatocytes is the foundation for another 
circulation within the liver named cholehepatic shunt (Benedetti et al., 1997; 
Meier and Stieger, 2002).  
 
In contrast to NTCP, the spectrum of ASBT substrates is considered narrow. 
Initially, it was thought that ASBT can only transport taurine- or glycine-
conjugated and unconjugated bile acids (Dawson, 2011). However, recent 
evidence shows that it is capable of transporting bile acid analogs (Kolhatkar and 
Polli, 2012). Conjugates at C-3 or C-7 were synthesized and tested for uptake 
studies. It turned out that a C-3 but not a C-7 modification of bile acids still 
afforded translocation by NTCP and ASBT.  These results suggest that it should 
be possible to target ASBT and NTCP by conjugating drugs to the C-3 hydroxyl 
group of bile acids for therapeutic purposes.  
 
Since ASBT is critical for maintaining bile acid homeostasis, it is important to 
know if a drug could influence its function or expression. Several studies have 
shown that the expression level of ASBT mRNA increased in the kidney and 
ileum with vitamin D treatment in response to the activation of the vitamin D 
	  8	  
receptor (Chow et al., 2010; Chow et al., 2011). Another study showed that mice 
treated with ampicillin exhibited elevated ASBT levels due to the disturbance of 
the intestinal flora which produce secondary bile acids (Miyata et al., 2011). 
Furthermore, Zheng et al. demonstrated, using MDCK cells stably expressing 
ASBT, that statins and dihydropyridine calcium channel blockers are potent 
inhibitors of ASBT (Zheng et al., 2010). These results suggest that there indeed 
is a potential for drug-drug interaction at ASBT in vivo. 
 
ASBT is an emerging therapeutic target for dyslipidemia, cholestasis, diabetes 
and chronic constipation. When ASBT is inhibited, bile acid reabsorption from the 
ileum is impeded and therefore the liver uses more cholesterol to make bile acids. 
Several ASBT inhibitors have been tested for their lipid lowering effects. For 
instance, a newly synthesized ASBT inhibitor, Polyacrylic acid-tetraDOCA 
conjugate, prevents the increase of cholesterol in the blood as well as triglyceride 
in the liver in mice fed a high fat diet (Park et al., 2015). A selective inhibitor of 
ASBT, A4250, attenuates cholestatic liver and bile duct injury in mice by reducing 
biliary bile acid concentrations (Baghdasaryan et al., 2016). In addition, 264W94, 
a first generation ASBT inhibitor, is a possible new treatment for type 2 diabetes 
(Chen et al., 2012). More recently, GSK2330672 was discovered as a highly 
potent, non-absorbable ASBT inhibitor, which lowers glucose in diabetic animals. 
It shows excellent develop-ability properties for the treatment of patients with 
type 2 diabetes (Wu et al., 2013). Last but not the least, A3309, a minimally 
absorbed ASBT inhibitor, increases stool frequency and improves constipation-
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related symptoms in patients; these effects were maintained over 8 weeks of 
treatment.  (Chey et al., 2011).  
 
   
B. The SLCO superfamily 
1) Overview 
Besides sodium-dependent transporters, sodium-independent transporters, such 
as OATPs, also mediate the influx of bile acids into cells. OATPs are encoded by 
SLCO genes. 
 
Rat OATP1A1 was the first OATP that was cloned (Jacquemin et al., 1994) and 
the first human OATP, OATP1A2 was cloned a year later (Kullak-Ublick et al., 
1995). Until now, more than 300 members of the OATP superfamily have been 
identified and/or predicted from over 40 species, such as human, monkey, dog, 
pig, rat, mouse and fish. Among all of them, human and rodent OATPs are the 
most extensively studied and characterized. Based on their amino acid 
similarities, human and rodent OATPs are classified into 6 families, namely 
OATP1, OATP2, OATP3, OATP4, OATP5 and OATP6. Within each family, there 
can be subfamilies. For example, the OATP1 family contains the subfamilies 
OATP1A, OATP1B and OATP1C (Hagenbuch and Stieger, 2013). 
 
2) Distribution and substrate specificity 
Among all the human and rat SLCO superfamily members, the OATP1 and 
OATP2 family members are the most well-characterized. Table 1-1 lists the 
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localization and representative substrates of human and rat OATP1 and OATP2 
family members. OATP1A2 is the only human OATP1A subfamily member while 
in rats 5 members have been identified. In contrast to the OATP1A subfamily, the 
OATP1B subfamily contains only one rodent (OATP1B2) but two human 
members, OATP1B1 and OATP1B3 (Hagenbuch and Stieger, 2013). 
 
Unlike NTCP and ASBT, OATPs mediate the transport of a broad spectrum of 
structurally diverse compounds with overlapping substrate specificities as 
indicated in Table 1-1 (Roth et al., 2012; Hagenbuch and Stieger, 2013). Bile 
salts, steroid and thyroid hormones are common endogenous substrates of 
OATPs with the exception that OATP2A1 mainly transports prostaglandins. 
Additionally, many xenobiotics, including numerous drugs, are substrates of 
OATPs. This can lead to drug-drug and drug-food interactions, like the interaction 














Table 1-1: Brief summary of the OATP1 and OATP2 subfamily members 
 
 
Subfamily Species Transporter Distribution Selected substrates 
OATP1A 









OATP1A1 Liver, kidney, brain 
OATP1A3 Kidney 
OATP1A4 Liver, brain, eye 









































OATP2A Human OATP2A1 Ubiquitous Prostaglandins Rat OATP2A1 Ubiquitous Prostaglandins 
OATP2B 














3) Regulation of expression 
Transcriptional regulation is largely involved in the control of OATP expression. 
Expression of OATP1B1 and OATP1B3 in hepatocytes is controlled by 
hepatocyte nuclear factor 1α (HNF1α) (Jung et al., 2001) and HNF3β (Vavricka 
et al., 2004), respectively. In addition, other transcription factors like PXR, FXR 
and LXR play roles in the regulation of OATP1B1 expression (Meyer Zu 
Schwabedissen et al., 2010; Suzuki et al., 2011). Furthermore, PXR and CAR 
regulate the expression of OATP1A2 (Meyer zu Schwabedissen et al., 2008).  
 
Post-translational regulation also occurs for OATPs. The C-terminal end of 
OATP1A2 can interact with PDZ proteins, potentially leading to its membrane 
localization (Kato et al., 2004). Phosphorylation affects membrane expression of 
rat OATP1A1 (Choi et al., 2011). In addition, activation of protein kinase C 
regulates the function of OATP1B1, OATP1B3 and OATP2B1 via triggering the 
rapid internalization and recycling of these transporter proteins. (Kock et al., 2010; 
Powell et al., 2014; Hong et al., 2015).  
 
4)  Clinical significance 
So far, only a few diseases have been linked to OATP function. One example is 
Rotor syndrome, a rare, benign syndrome presenting with unconjugated and 
conjugated hyperbilirubinemia. It results from disruption of hepatic uptake of 
bilirubin glucuronide due to complete functional OATP1B1 and OATP1B3 
deficiency (van de Steeg et al., 2012). However, many studies have shown that 
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altered OATP expression levels resulting from single-nucleotide polymorphisms 
(SNPs) and/or allele deletion can disturb normal pharmacokinetics. Various 
polymorphisms of OATP1B1 have been identified and characterized. Two 
common SNPs are the SLCO1B1 388A>G and 521T>C alleles, which can form 
four distinct haplotypes, including *1A (c.388A-c.521T), *1B (c.388G-c.521T), *5 
(c.388A-c.521C), and *15 (c.388G-c.521C) (Niemi et al., 2011). Presence of 
SLCO1B1*15 can lead to a higher risk for developing severe hyperbilirubinemia 
in neonates (Buyukkale et al., 2011) and to higher serum bilirubin levels in adults 
(Ieiri et al., 2004). Carriers of SLCO1B1*5 and *15 haplotypes, individuals with 
these haplotypes have increased plasma levels of drugs such as pravastatin 
(Nishizato et al., 2003), pitavastatin (Chung et al., 2005), and atrasentan (Katz et 
al., 2006) due to reduced transport function of these mutant OATP1B1 proteins. 
Given the importance of OATPs expressed in hepatocytes for drug elimination, 
the FDA requires OATP-inhibition studies for all drugs, and, for certain drugs, 
even uptake studies, following the recommendations of The International 
Transporter Consortium (Giacomini et al., 2010). 
  
  
C. Brief introduction to OSTα-OSTβ (SLC51A family) 
The organic solute transporter alpha-beta (OSTα-OSTβ) is one of the most 
unique members in the SLC family because the functional transporter consists of 
two different proteins. It was cloned from the liver of the little skate (Leuroraja 
erinacea) by Wang et al in 2001 (Wang et al., 2001). The mouse and human 
orthologs were subsequently cloned and characterized by Seward et al. in 2003 
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(Seward et al., 2003). OSTα is encoded by the SLC51A gene, has 340-amino 
acids and is predicted to have a 7- transmembrane domain structure.  OSTβ is a 
128-amino acid single-transmembrane domain polypeptide and encoded by 
SLC51B. In contrast to other organic anion transporters, heterodimerization of 
OSTα and OSTβ is required for transport activity.  
 
OSTα and OSTβ are ubiquitously expressed throughout the body but highest 
expression levels are found in tissues involved in bile acid and steroid 
homeostasis, such as intestine, liver (Fig 1-1) and kidney. Depending on the 
concentration gradient, OSTα-OSTβ is capable of mediating influx as well as 
efflux of substrates along their gradient. OSTα-OSTβ is a key player in the 
enterohepatic circulation. At the basolateral membrane of enterocytes, OSTα-
OSTβ is responsible for the excretion of bile acids reabsorbed by ASBT from the 
ileum into the portal circulation. OSTα-OSTβ is a multispecific transporter and 
substrates besides bile acids include estrone-3-sulfate, digoxin, prostaglandin E2 
and DHEAS. (Ballatori et al., 2009; Ballatori et al., 2013) 
 
D.        Brief introduction to OATs (SLC22A family)  
The SLC22A family contains transporters for organic anions (OATs), organic 
cations (OCTs) and zwitterions (organic zwitterions/cation transporters (OCTNs)) 
(Koepsell, 2013). OATs are multispecific transporters mainly localized in the 
kidney where they mediate the excretion with the exception of OAT4, which 
mediates the reabsorption of organic anions, including endogenous solutes and 
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numerous xenobiotics including drugs. Compared to OATPs, which mainly 
transport large hydrophobic organic anions, substrates of OATs are smaller and 
more hydrophilic organic anions (Roth et al., 2012). 
  
At present, no crystal structure exists for any of the OATs. However, based on 
amino acid sequence analysis and homology modeling, OATs have a predicted 
structure consisting of 12 α-helical transmembrane domains, a large extracellular 
loop between transmembrane domain 1 and 2 as well as a large intracellular loop 
between transmembrane domain 6 and 7. Among the different OATs, OAT1, 
OAT2, OAT3 and OAT4 are well characterized (Koepsell, 2013). 
 
The first mammalian OAT, rat OAT1 was cloned in 1997 (Sweet et al., 1997), the 
first human OAT1 was subsequently identified in the following year (Reid et al., 
1998). The main expression site of OAT1 is at the basolateral membrane of 
proximal tubules in the kidney, mediating the secretion of organic anions. To a 
lesser extent, OAT1 is also expressed in the skeletal muscle and choroid plexus. 
Endogenous substrates of OAT1 include medium chain fatty acids, α-
ketoglutarate, cAMP and cGMP, prostaglandins, and urate. In addition, OAT1 
can transport various drugs like the antibiotic tetracycline and antiviral drugs such 
as acyclovir and adefovir (Rizwan and Burckhardt, 2007; Burckhardt, 2012). 
 
OAT2 is mainly found at the basolateral membrane of the liver. In the kidney, 
human OAT2 is also expressed at the basolateral membrane of proximal tubules 
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while rodent OAT2 is localized at the apical membrane. OAT2 transports 
endogenous compounds such as glutamate, urate, purine and pyrimidine 
nucleobases, nucleosides and nucleotides. Many drugs including salicylate, 
bumetanide and tetracycline are also substrates of OAT2 (Rizwan and 
Burckhardt, 2007; Burckhardt, 2012). 
 
Along with OAT1, OAT3 is highly expressed at the basolateral membrane of 
proximal tubule cells. OAT3 mRNA is also detected in the spinal cord, choroid 
plexus, eye and adrenal gland. Among all the OATs expressed in human kidney 
(OAT1-4), OAT3 is the most abundantly expressed (Motohashi et al., 2002). 
OAT3 transport is coupled to the efflux of α-ketoglutarate. Endogenous 
substrates of OAT3 include cAMP, cortisol, prostaglandins, DHEAS, estrone-3-
sulfate, taurocholate and urate. Drugs that can be transported by OAT3 include 
β-Lactam-antibiotics, H2 antagonists, antiepileptic, cytostatics, diuretics, NSAIDs, 
statins and uricosurics (Rizwan and Burckhardt, 2007; Burckhardt, 2012). 
 
OAT4 is only expressed in humans. It is located at the apical membrane of 
proximal tubule epithelial cells and at the placental epithelial basolateral 
membrane. Human OAT4 transports conjugated hormones such as estrone-3-
sulfate, DHEAS, and prostaglandins. Drugs that interact with OAT4 are very 
similar to the drugs that interact with OAT1-3, including antibiotics, diuretics, 
statins and antivirals (Rizwan and Burckhardt, 2007). 
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E. Brief introduction to ABC transporters in the liver and intestine 
ABC transporters use energy from ATP hydrolysis to move a wide range of 
molecules out of mammalian cell membranes as well as intracellular membranes 
against their electrochemical gradient. These proteins are encoded by ABC gene. 
Fourty-nine ABC genes exist in humans, classified into seven subfamilies, from 
ABCA to ABCG. Substrates of ABC transporters include metal ions, peptides, 
amino acids, sugars and a large number of hydrophobic compounds and 
metabolites (Vasiliou et al., 2009). 
 
Together with influx transporters, ABC transporters facilitate the movement of 
solutes across the enterocytes and hepatocytes by mediating their efflux. As 
shown in Fig 1-1, at the canalicular membrane of hepatocytes, ABC pumps 
including P-glycoprotein (P-gp), BSEP, multidrug resistance associated protein 2 
(MRP2), and breast cancer resistance protein (BCRP) are expressed, while 
MRP3 is located at the sinusoidal membrane. In enterocytes, P-gp, MRP2 and 
BCRP are found at the apical membrane and MRP3 is expressed at the 
basolateral membrane. Table 1-2 summarizes the encoding genes, tissue 







Table 1-2: Brief summary of ABC transporters in hepatocytes and 
enterocytes (Dean et al., 2001) 







Neutral and cationic organic 
compounds, 
drugs (e.g. vinblastine, doxorubicin, 
paclitaxel, methotrexate, losartan) 





Non-bile salt organic anions, 





























P-gp was first demonstrated to confer resistance to colchicine in CHO cells 
(Juliano and Ling, 1976) and then was shown to confer resistance to a wide 
range of amphiphilic drugs. Substrates of P-gp are usually bulky, hydrophobic 
organic cations. Expressed at the apical membranes of epithelial cells, it has 
great influence on drug disposition by limiting absorption in the intestine and 
enhancing urinary and biliary excretion in the kidney and liver, respectively. The 
drug resistance role of P-gp expressed in the placenta and at the blood-brain-
barrier largely contributes to the protection mechanism of these important 
compartments (Honjo et al., 2002; Kock and Brouwer, 2012). 
 
In contrast to P-gp, BSEP has a narrow substrate spectrum and mainly 
transports bile salts. BSEP is exclusively expressed at hepatocyte canalicular 
membrane, where it is responsible for the excretion of bile acids into the bile 
ducts and therefore constitutes the major driving force for the generation of bile 
salt-dependent bile flow (Stieger, 2011).  
 
Two ABCC subfamily members, MRP2 at the apical membrane and MRP3 at the 
basolateral membrane, are usually found in epithelial cells, especially in the 
intestine, liver and kidney. Organic anions are common substrates of MRPs while 
they can also mediate the efflux of certain uncharged amphipathic, or even 
cationic compounds (Slot et al., 2011).  
 
ABCG genes encode half-transporters that must form homo- or heterodimers for 
function (Vasiliou et al., 2009). BCRP is the only member of this subfamily that is 
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involved in drug transport. Similar to P-gp, BCRP was initially identified in drug-
resistant cancer cell lines and then was found to locate to the apical membrane 
of epithelial cells in many organs protecting them from toxicants. Numerous 
chemotherapeutics and hydrophobic organic anions are substrates of BCRP. 
   
III. Introduction to perfluoroalkyl substances (PFASs) 
A. Terminology and classification 
Perfluoroalkyl substances (PFASs) are defined as aliphatic substances for which 
all of the H atoms on the carbon backbone are replaced by F atoms, except 
those H atoms whose substitution would modify the nature of any functional 
groups present (Buck et al., 2011). Depending on the functional group, PFASs 
are divided into the two families of the perfluoroalkyl carboxylates (PFCAs) and 
the perfluoroalky sulfonates (PFSAs). Within each family, PFASs are frequently 
referred to as “long-chain” or “short-chain”. Defined by the Organization for 
Economic Co-operation and Development, “long-chain” refers to PFCAs with 8 or 
more carbons, and to PFSAs with 6 or more carbons (Buck et al., 2011). Fig. 1-2 
shows two examples of long-chain PFASs, perfluorooctanoic acid (PFOA) with 7 
fluorinated carbons and one additional carbon in the functional group, and 






Figure 1-2: Examples of long-chain PFCAs and PFSAs 












B. Environmental contamination by PFASs. 
Since the 1940s, precursors of PFASs or PFASs themselves have been widely 
used in the industry as surfactants due to their extremely stable Carbon-Fluorine 
bonds.  PFOS and PFOA are ubiquitously distributed in the environment. Once 
released into the environment, some higher molecular weight PFASs degrade to 
PFCAs and PFSAs, primarily to PFOA and PFOS (Buck et al., 2011). On the 
other hand, the strong Carbon-Fluorine bond also makes PFCAs and PFASs 
highly resistant to degradation and therefore persistent in the environment. Since 
the first reported global distribution of PFOS in wildlife liver and blood (Giesy and 
Kannan, 2001), increasing amounts of samples collected from biota and humans 
have been analyzed. To date, data are available for the distribution of certain 
members of the PFASs, mainly for PFOS, PFOA, PFHxS and some others, in 
surface water, sediments, wildlife as well as in humans from many countries 
(Higgins et al., 2005; Houde et al., 2011). Since these compounds can migrate 
via air and water, PFOA and PFOS are even detectable in the most remote 
oceanic areas and are even found in polar bears (Giesy and Kannan, 2001; 
Smithwick et al., 2005). Production of PFOS and PFOA was phased-out in the 
USA between 2000 and 2002 and short-chain PFASs were developed to replace 
the phased-out compounds.  
 
C. Concentrations and half-lives of PFASs in humans 
PFOS, PFHxS, perfluorononanoic acid (PFNA) and PFOA are found in nearly all 
people tested. According to the National Health and Nutrition Examination 
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Survey (NHANES) 2003-2004, the range of serum PFOS, PFOA, PFHxS and 
PFNA was 0.4 µg/L to 435 µg/L, 0.1 µg/L to 77.2 µg/L, 0.3 µg/L to 82.0 µg/L and 
0.1 µg/L to 11.5 µg/L, respectively, in the general U.S. population (Calafat et al., 
2007). Results of the survey also indicated that concentrations of PFOS, PFOA 
and PFHxS are significantly higher in males than in females. In comparison with 
the general population, occupational workers have much higher serum 
concentrations of PFOS (145-3490 ng/ml), PFHxS (16-1295 ng/ml) and PFOA 
(72-5100 ng/ml) (Olsen et al., 2007). Furthermore, a comparison of serum 
concentrations of PFASs in children demonstrated that, in general, children have 
higher serum concentrations than adolescents and adults (Olsen et al., 2004; 
Kato et al., 2009b). It was suggested that this might be due to a unique exposure 
pattern for children, such as e.g. playing on carpets treated with PFASs. The 
main routes of human exposure include oral, through dietary intake and drinking 
water, and by inhalation from consumer products, indoor air and/or dust (Begley 
et al., 2005; Emmett et al., 2006; Kato et al., 2009a; Noorlander et al., 2011; 
Domingo et al., 2012). Since 1999-2000, serum levels of PFOS and PFOA have 
decreased gradually in U.S. residents (Centers for Disease Control and 
Prevention, 2015). Serum elimination half-lives of PFASs in humans are very 
long. Olsen et al. estimated from retired fluorochemical workers that the mean 
serum elimination half-lives for PFOS, PFHxS and PFOA are 4.6, 7.1 and 3.4 
years, respectively (Olsen et al., 2007). The short-chain PFBS is estimated to 
have a half-life of 26 days from 6 human subjects (Olsen et al., 2009). Further 
analysis is needed for a more accurate evaluation of the half-lives of PFASs in 
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humans and for comparison between different populations, such as between 
males and female as well as among children, adults and elderly. 
 
D. Toxicities of PFASs 
Exposure to high doses of PFOA increased the incidence of hepatocellular 
adenomas, thyroid follicular cell adenomas, Leydig cell tumors, and pancreatic 
acinar cell tumors in rats (Lau et al., 2007; Andersen et al., 2008). In non-human 
primates, repeated high doses of PFOS treatment showed reduced body weight, 
increased liver weight and reduced cholesterol levels while no significant adverse 
effects was observed in monkeys treated with lower doses (Seacat et al., 2002). 
Other toxic effects, such as developmental toxicity (Lau et al., 2004; Lau et al., 
2007), immune depression (Corsini et al., 2014), altered weight gain after in utero 
exposure (Hines et al., 2009) and thyroid hormone disruption (Lau et al., 2007), 
were also observed with high dose of PFOS. Epidemiological studies found a 
direct association between PFOS and PFOA levels and serum cholesterol levels 
in humans (Frisbee et al., 2010; Nelson et al., 2010). An association between 
PFOA levels and kidney and testicular cancer among adults who lived in the Mid-
Ohio Valley and were exposed to PFOA in the drinking water due to chemical 
plant emissions was also indicated (Barry et al., 2013). 
 
No genotoxic effect has been seen with any of the PFASs. Activation of 
peroxisome proliferator-activated receptor-alpha (PPARα) contributes to most of 
the toxic effects in rodents (Andersen et al., 2008). In addition to PPARα, 
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activation of nuclear receptors including CAR and PXR in hepatocytes was 
observed in rodents (Ren et al., 2009; Bjork et al., 2011; Elcombe et al., 2012). A 
recent study by Beggs, et al. revealed that HNF4α degradation might play a role 
in PFOA and PFOS induced steatosis and tumorigenesis in human livers (Beggs 
et al., 2016).  
  
E. Toxicokinetic properties of PFASs in laboratory animals 
To date, pharmacokinetic parameters for PFBA (Chang et al., 2008), PFHxA 
(Chengelis et al., 2009), PFOA (Butenhoff et al., 2004; Hinderliter et al., 2005; 
Hinderliter et al., 2006a; Hinderliter et al., 2006b; Olsen et al., 2007), PFHpA, 
PFNA, PFDA, PFBS (Chengelis et al., 2009; Olsen et al., 2009), PFHxS (Olsen 
et al., 2007; Sundstrom et al., 2012) and PFOS (Olsen et al., 2007; Chang et al., 
2012) were studied in at least one species. Both similarities and differences were 
observed between species, genders as well as among individual PFASs. In 
terms of similarities, most of the compounds are readily absorbed after oral 
administration in rats (Chang et al., 2008; Olsen et al., 2009; Sundstrom et al., 
2012) with the exception of PFOS (Chang et al., 2012). The other comparatively 
consistent parameter is the apparent volume of distribution, which is around 200 
to 300 ml/kg body weight (corresponding to the extracellular space). Animal 
studies also demonstrated that PFASs predominantly distribute into plasma and 
well perfused tissues, such as liver, kidney and lung, and that they are not 
metabolized in the body because of their extreme stability (Vanden Heuvel et al., 
1991). Serum protein binding is another feature for PFASs observed in laboratory 
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animals and humans (Vanden Heuvel et al., 1991). For example, around 98% of 
PFOA is bound to rat serum proteins (Hanhijarvi et al., 1982). As a consequence, 
the renal elimination is limited to the free fraction of PFASs. 
 
F. Renal elimination of PFASs  
The major route of elimination for PFASs, especially short-chain PFASs, is 
through urine in animal models. Since the first observation that renal elimination 
of PFOA is faster in female than in male rats (Vanden Heuvel et al., 1991), sex-
dependent clearance has been reported for various PFASs (Ohmori et al., 2003; 
Chang et al., 2008; Chengelis et al., 2009; Gannon et al., 2011; Sundstrom et al., 
2012). Additionally, when comparing the pharmacokinetic parameters in different 
species, the elimination half-lives of PFASs differ significantly. Taking the most 
extensively studied PFOA for example, the elimination half-life ranges from hours 
to years (1.9 h for female rats, 5.5 h for female rabbits, 7 h for male rabbits, 5.6 d 
for male mice, 5.6 d for male rats, 15.6 d for female mice, 21.7 d for male mice, 
20.9 d for female monkeys, 32.6 d for male monkeys and 3.5 y for humans). 
Furthermore, a chain length-dependent trend of clearance and elimination half-
life of PFCAs was demonstrated in which the total clearance decreases along 
with the chain length (Ohmori et al., 2003; Han et al., 2012). Although not as 
dramatic as PFCAs, the clearance of PFSAs shares similar species-, gender- 
and chain length-dependent pattern.  Overall, short-chain PFASs (including 
PFBA, PFHxA, PFHpA, PFBS, PFHxS) for both sexes and long-chain PFASs 
(including PFOA and PFNA) for females are readily cleared from the serum in 
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rats, while the renal clearance for long-chain PFASs (including PFOA and PFNA 




































Rats 4.5 3.9 




Rats 29.1 1.6 
(Sundstrom et al., 
2012) Mice 30.5 24.8 
Monkeys 141 87 
Humans 2665 (Olsen et al., 2007) 
PFOS 
(C8+S) 
Rats 38.3 62.3 
(Chang et al., 
2012) Mice 42.8 37.8 
Monkeys 132 110 















G. Long-chain PFASs accumulate in the liver 
Despite more than 90% are bound to plasma protein, the liver-to-plasma ratio of 
long-chain PFASs is generally higher than 1 in laboratory animals and humans, 
indicating that long-chain PFASs accumulate in the liver (Seacat et al., 2002; 
Olsen et al., 2003; Hundley et al., 2006; Kudo et al., 2007; Chang et al., 2012). 
For instance, the dose recovered from the liver in rats treated with both low-dose 
and high-dose of PFOA was the highest among all the organs (52% and 27%, 
respectively). Furthermore, the percentage is considerably higher at the 
environmentally relevant low dose treatment. However, the only available liver-to-
serum ratio of PFOA in humans is around 1 by measurement from pooled human 
tissues (Maestri et al., 2006). PFOS, on the other hand, was shown to have a 
higher liver-to-plasma ratio in rats [1.7:1, mean value (Chang et al., 2012)], mice 
[4:1 with low dose and 1.5:1 with high dose (Bogdanska et al., 2011)], monkeys 
[1.8: 1, mean value (Seacat et al., 2002)] and humans [1.3: 1, mean value (Olsen 
et al., 2003)]. The proposed mechanisms for high liver uptake of PFOA and 
PFOS include their binding to lipid-binding and/or xenobiotic-binding proteins in 
the liver and being potential substrates for hepatic transporters (Bogdanska et al., 
2011). 
 
IV. Concluding remarks for the introduction 
Membrane transporter proteins, especially SLC and ABC transporters expressed 
in the liver, intestine and kidney play important roles in the disposition of 
xenobiotics. Previous pharmacokinetic analysis for PFASs reveals species and 
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chain-length differences in their excretion and particularly long half-lives of PFOA, 
PFHxS and PFOS in humans. Drug transporters likely contribute to these 
pharmacokinetic characteristics. Identification of which transporters are required 
for the pharmacokinetic characteristics of PFASs is required to answer these 
questions: 1) What transporters make it possible for the enterohepatic 
circulation of PFOA, PFHxS and PFOS; 2) Are transporters responsible for 
the gender dependent excretion of PFASs; 3) Do transporters play a role in 
the chain length dependent excretion of PFASs. 
  
V. Specific aims of this dissertation 
The overall goal of my research was to identify and characterize liver, intestinal 
and kidney transporters that are involved in the liver accumulation and renal 
clearance of PFCAs and PFSAs in rats and humans. In presenting this 
dissertation, I will defend two specific aims. 
Specific aim 1 evaluates the hypothesis that liver and intestinal transporters 
are involved in the disposition of PFASs. To address this aim, freshly isolated 
human and rat hepatocytes were used for PFSA uptake measurements. Then, 
the interactions of PFSAs with uptake transporters expressed in hepatocytes and 
enterocytes in humans and rats were demonstrated using immortalized cell lines 
that overexpress individual transporters. Furthermore, the inhibition of efflux 
transporters expressed at the canalicular membrane of hepatocytes by PFSAs as 
well as uptake of PFSAs by OSTα-OSTβ expressed at the basolateral membrane 
of enterocytes were also investigated. The purpose of this study was to identify 
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the mechanism of the long half-lives of PFOA, PFHxS and PFOS by identifying 
the liver and intestinal transporters involved in the uptake and efflux of individual 
PFASs. 
Specific aim 2 evaluates the hypothesis that the differences of renal clearance 
of PFASs among different species, genders and chain lengths are due to 
the differences of specific transporters expressed in the kidney. To address 
this aim, rat renal transporters OAT1, OAT3 and OATP1A1 were examined for 
the transport of PFBS, PFHxS and PFOS. The purpose of this study was to 
identify the renal transporters that contribute to the chain length differences in the 




Materials and methods 
 
I. Materials 
Radiolabelled [3H]-taurocholate and [3H]-estrone-3-sulfate were purchased from 
PerkinElmer (Boston, Massachusetts), potassium perfluorobutane sulfonate 
(K+PFBS, 98.2% pure), potassium perfluorohexane sulfonate (K+PFHxS, >99% 
pure), and potassium perfluorooctane sulfonate (K+PFOS, 86.9% pure) were 
received from the 3M Company (St. Paul, Minnesota). Perfluoroalkyl 
carboxylates (C7-C10) were purchased from Sigma Aldrich (St Louis, MO).  
 
II. Construction of plasmids 
A human NTCP (hNTCP) containing pSport1 vector (Hagenbuch and Meier, 
1994) was digested with restriction enzyme Kpn I and BamH I, and the resulting 
hNTCP cDNA was inserted into the pcDNA5/FRT vector.  
 
The human ASBT (hASBT) cDNA was sub-cloned from a plasmid purchased 
from Open Biosystems (OHS6084-202630699, Lafayette, CO) into the 
pcDNA5/FRT expression vector using PCR and restriction digestion with the 
primers shown in Table 2-1.  
 
The human OSTα cDNA in pCMV6-XL4 (Origene SC100623, NCBI NM_152672) 
was digested with NotI and inserted into pcDNA5/FRT vector. The human OSTβ 
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cDNA in pCMV6-Entry (Origene (RC517638, NCBI NM_178859) was sub-cloned 
into pcDNA5/FRT using primers in Table 2-1. 
 
Rat NTCP (rNTCP) was cloned into the pcDNA5/FRT expression vector from a 
cell line overexpressing rat NTCP (Schroeder et al., 1998) using the primers as 
indicated in Table 2-1.  
 
The rat ASBT (rASBT) cDNA was subcloned from a plasmid purchased from 
Origene (NM_017222, RN209999, Rockville, Maryland) into the pcDNA5/FRT 
vector using primers and restriction enzymes listed in Table 2-1. 
 
The open reading frames of rOATP1B2 and rOATP2B1 were PCR amplified to 
include a C-terminal 6 His-tag using the primers containing the restriction sites 
listed in Table 2-1 from a pSport-1 vector containing the respective cDNAs.  
 
The open reading frames of rOATP1A1 and rOATP1A5 were subcloned using 
restriction enzymes from a pSport1 vector containing the cDNA of rOATP1A1 or 
rOATP1A5 into a pExpress1 or a pCMV-pSport6 vector, respectively. 












Table 2-1: Primers used for cloning 
	  
	  

























































III. Cell lines and tissue culture 
Chinese Hamster Ovary (CHO) Flp-In cells were transfected with the hNTCP-
pcDNA5/FRT construct to generate a stable hNTCP expressing cell line.The 
generation of Chinese Hamster Ovary (CHO) cells stably expressing human 
OATP1B1 and OATP1B3 as well as the CHO Flp-In cells expressing hOATP2B1 
were described previously (Gui et al., 2008; Pacyniak et al., 2010). 
 
CHO Flp-In cells were grown at 37 °C in a humidified 5% CO2 atmosphere in 
Dulbecco’s Modified Eagle Medium (DMEM) with 1 g/l D-glucose, 2 mM L-
glutamine, 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
buffer, and 110 mg/l sodium pyruvate supplemented with 10% fetal bovine serum 
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(FBS) (Hyclone, Logan, Utah), 50 mg/ml L-proline, 100 U/ml penicillin, 100 mg/ml 
streptomycin (Invitrogen), and 500 mg/ml hygromycin (Invitrogen, Carlsbad, 
California).  
CHO cells were maintained at 37 °C in a humidified 5% CO2 atmosphere in 
DMEM with 1 g/l D-glucose, 2 mM L-glutamine, 25 mM HEPES buffer, and 110 
mg/l sodium pyruvate supplemented with 10% FBS, 50 mg/ml L-proline, 100 
U/ml penicillin, 100 mg/ml streptomycin and 0.5 mg/ml geneticin (not for wild-type 
cells).  
Human embryonic kidney (HEK293) cells (HEK293T/17-CRL-11268, ATCC, 
Manassas, Virginia) were grown at 37 °C in a humidified 5% CO2 atmosphere in 
DMEM High Glucose supplemented with 10% FBS, 100 U/ml penicillin, and 100 
mg/ ml streptomycin.  
Human and rat hepatocytes were isolated by the Cell Isolation Core in the 
Department of Pharmacology, Toxicology and Therapeutics at the University of 
Kansas Medical Center as described (Xie et al., 2014). All human liver 
specimens were obtained in accordance with Human Subjects Committee (HSC) 
at University of Kansas Medical Center approved protocol from patients 
undergoing hepatic resection procedures or from donor organs. The hepatocytes 
were then seeded at 250,000 cells per well on collagen-coated 24-well plates 
and allowed to attach in a humidified 37 °C, 5% CO2 incubator. Uptake with 
human hepatocytes was determined 24h after plating and uptake with rat 
hepatocytes was measured 3 h after plating. 
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IV. Transporter expression in stable cell lines 
For uptake assays, CHO-hNTCP or CHO-hOATP2B1 cells were plated at 40,000 
cells per well on 24-well plates and 72h later used for uptake experiments. 
Medium was changed when needed.  
CHO-WT, CHO-OATP1B1, CHO-OATP1B3 cells were plated at 30,000 cells per 
well on 24-well plates and induced with 5 mM sodium butyrate after 48 hours. 
Twenty-four hours after induction, cells were used for uptake experiments. 
 
V. Transporter expression in HEK293 cells 
HEK293 cells were plated at 20,0000 cells per well in 24-well plates coated with 
0.1 mg/ml poly-D-lysine. Twenty-four hours later, cells were transfected with 0.5 
mg plasmid DNA and 1.5 ml Fugene HD (Promega, Madison, Wisconsin) per 
well and uptake assays were performed 48 h later. Medium was changed when 
needed. 
 
VI. Cell-based transport assay 
Cells were washed three times with 1 ml of pre-warmed (37 °C) CHO uptake 
buffer (116.4 mM NaCl or choline chloride, 5.3 mM KCl, 1 mM NaH2PO4, 0.8 mM 
MgSO4, 5.5 mM D-glucose, and 20 mM HEPES, pH adjusted to 7.4 with Tris-
base), HEK293 uptake buffer (142 mM NaCl or choline chloride, 5 mM KCl, 1 
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mM KH2PO4, 1.2 mM MgSO4, 1.5 mM CaCl2, 5 mM glucose, and 12.5 mM 
HEPES, pH 7.4), or hepatocyte uptake buffer (136 mM NaCl or choline chloride, 
5.3 mM KCl, 1.1 mM KH2PO4, 0.8 mM MgSO4, 1.8 mM CaCl2, 11 mM glucose, 
and 10 mM HEPES, pH 7.4). Then, 200 µl uptake buffer (37 °C) containing 
PFASs or radiolabeled model substrates were added to the well to initiate 
transport.  Uptake was terminated at indicated time points by two 1-ml washes 
with ice-cold uptake buffer containing 3% bovine serum albumin and two 1-ml 
washes with plain ice-cold uptake buffer. Cells were lysed with 200 µl 1% Triton 
X-100 in H2O for PFASs or 300 µl 1% Triton X-100 in PBS for radiolabeled 
substrates at room temperature for 20 min. For PFASs, 120 µl cell lysate was 
used for liquid chromatography-tandem mass spectrometry (LC-MS/MS). For 
radiolabeled substrates, 200 µl of cell lysate was transferred to a 24-well 
scintillation plate (Perkin Billerica, MA) and 750 µl Optiphase Supermix 
scintillation cocktail (Perkin Elmer, Waltham, MA) was added to each well. 
Radioactivity was measured in a Microbeta liquid scintillation counter (Perkin 
Elmer, Waltham, MA). The remaining cell lysates were transferred to 96-well 
plates to determine the total protein concentration using the bicinchoninic acid 
protein assay (Pierce Biotechnology, Inc. Rockford, IL). All transport 
measurements were corrected by the total protein concentration. All experiments 
were performed two to four times independently with triplicate determinations. 
 
VII. Sf9 vesicle transport 
Sf9 vesicles overexpressing human MRP2, BCRP or BSEP were purchased from 
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Corning Incorporated (Tewksbury, MA).  Fifty µg human MRP2, BCRP or BSEP 
Sf9 vesicles were incubated with model substrates 5(6)-carboxy-2’7’-
dichlorfluorescein (CDCF) (Corning gentest MRP/BCRP vesicle assay kit), [3H]-
estrone-3-sulfate or [3H]-taurocholate at 37 °C in the presence of 5 mM ATP or 
AMP for 15 min, 3 min or 30 min, respectively. The reaction was stopped by 
filtering the vesicle suspension through a 96-well glass fiber filter plate (Millipore, 
Merck KGaA, Darmstadt, Germany) on a MultiScreenHTS vacuum manifold 
(Millipore) and the filters were washed 6 times with ice-cold wash buffer from the 
corresponding vesicle assay kit (Corning).  For radiolabeled substrates, 
Optiphase Supermix scintillation cocktail was added to the filter and it was heat 
sealed and used directly for counting in a Microbeta liquid scintillation counter 
(Perkin Elmer). For the fluorescent substrate CDCF, 100 µl 0.1N NaOH was 
added to each well and the substrate was eluted into a fresh 96-well plate. 
Fluorescence was determined in a Synergy 2 plate reader (BioTek, Winooski, VT) 
at 485/525 nm. Transport was determined by subtracting the values in the 
presence of AMP from the values in the presence of ATP. All experiments were 
performed two times independently with triplicate determinations. 
 
VIII. LC-MS/MS analyses for PFBS, PFHxS,and PFOS  
Cell lysates collected (vide supra) were analyzed for PFBS, PFHxS, or PFOS by 
LC-MS/MS using the following procedures: 
(1).  Standard and sample preparation 
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A fixed amount of internal standard (either 18O2-PFBS, 18O2-PFHxS, or 18O2-
PFOS) was added to new disposable1.8-ml polypropylene microcentrifuge tubes 
containing 25 µl of either PFAS standard or lysate samples.  PFAS standards 
were prepared in the same buffer matrix as lysate samples.   
 
To all tubes, 175 µl of a solution containing 5% ammonium acetate (2 mM) and 
95% acetonitrile was added followed by vortex (approximately 5 seconds) and 
then centrifugation (2500 x g, 20 minutes, room temperature).  Subsequently, 
180 µl of the supernatant was aliquoted to a new 100 µl polypropylene auto 
sampler vial pending LC-MS/MS analyses.The reagent-grade water used for all 
the LC-MS/MS analyses was MilliQ deionized water that was further purified to 
remove residual traces of perfluorinated compounds by being pumped through a 
C-18 HPLC column prior to use.   
 
(2). LC-MS/MS Conditions 
The instrument used for analysis was an API 5000 mass spectrometer (Applied 
Biosystems / MDS-Sciex Instrument Corporation, Foster city, CA) configured with 
Turbo Ion Spray (pneumatically assisted electrospray ionization source) in 
negative ion mode.  Separation of the compounds was completed on a Mac-Mod 
ACE ® C-18, 5 µm, 75 x 2.1 mm i.d. HPLC column with a gradient flow rate of 
0.250 ml/min (dual column method) using the conditions specified in Table 2-2.   
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All source parameters were optimized under these conditions according to 
manufacturer’s guidelines.  Transition ions monitored were as follows: 
PFBS: 299 -> 80 amu; PFBS Internal Standard: dual 18O2-labeled PFBS: 303 -> 
84 amu; PFHxS: 399 -> 80 amu; PFHxS Internal Standard: triple 18O2-labeled 
PFHxS: 405 -> 86 amu; PFOS: 499 -> 80 amu; PFOS Internal Standard: dual 



















Table 2-2: HPLC separation conditions of PFBS, PFHxS,and PFOS 
The gradient was run with mobile phase A (2 mM ammonium acetate) and 
mobile phase B (acetonitrile). 
Time 
(min) 



















IX. Statistical analysis  
Data were analyzed for significant differences using one-way ANOVA followed by 
the Dunnett post-test for inhibition assays and Student’s t-test for one time point 




Na+/taurocholate cotransporting polypeptide (NTCP) and apical 
sodium dependent bile acid transporter (ASBT) are involved in 
the disposition of PFSAs in humans and rats 
	  
Published: Toxicological sciences 146:363-373. 
	  
I. Introduction 
Pefluoroalkyl sulfonates (PFSAs) are fluorinated fatty acid analogues used as 
surfactants in industrial and commercial applications (Kissa and Kissa, 2001; 
Buck et al., 2011).  Due to the unique physicochemical properties of the carbon-
fluorine bonds, certain PFSAs such as perfluorohexane sulfonate (PFHxS) and 
perfluorooctane sulfonate (PFOS) are resistant to environmental and biological 
degradation.  They are frequently detected in the environment (Calafat et al., 
2007; Fromme et al., 2009; Houde et al., 2011; Kato et al., 2011; Zhao et al., 
2012).  Consequently, PFOS has been nominated to the Stockholm Convention 
in 2009 as a persistent organic pollutant (Convention, 2009). 
 
Pharmacokinetic studies revealed that PFSAs primarily bind to serum proteins 
and that their clearance is species- and chain length-dependent (Andersen et al., 
2008). In Sprague Dawley rats, the estimated serum elimination half-life for 
PFOS (an eight-carbon homolog) is approximately one month (Chang et al., 
2012) whereas PFBS (a four-carbon homolog) is efficiently excreted in urine with 
an estimated serum half-life of 3.9-4.5 hours (Olsen et al., 2009).  In these rats, 
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there is a distinct gender-difference in the serum elimination of PFHxS (a six-
carbon homolog) in that the estimated half-lives are 30 days in male but only 2 
days in female rats (Sundstrom et al., 2012).  In cynomolgus monkeys, the 
estimated serum elimination half-lives for PFHxS and PFOS are approximately 
four months (Chang et al., 2012; Sundstrom et al., 2012); whereas, for PFBS the 
respective half-life is approximately 4 days (Olsen et al., 2009).  The estimated 
serum elimination half-lives of PFHxS and PFOS in human serum are several 
years (geometric means are 7.3 years [95% CI 5.8 – 9.2 years] and 4.8 years [95% 
CI 4.0 – 5.8 years], respectively) (Olsen et al., 2007).  In contrast, PFBS has an 
estimated geometric serum elimination half–life of 26 days (95% CI 16 – 40 days) 
(Olsen et al., 2009).  
 
Several studies have demonstrated that PFOS preferentially accumulates in the 
liver.  In Sprague Dawley rats given a single IV dose of 14C-radiolabelled PFOS, 
Chang et al. (2012) reported that 3% and 25% of the administered dose was 
recovered in plasma and liver, respectively, after 89 days. They also reported 
data for CD-1 mice and Sprague Dawley rats given single oral doses. The data 
demonstrated that liver PFOS concentrations were always higher than 
concurrent serum PFOS concentrations by a factor of approximately 2 to 3 at 
measured time points following dosing. This is consistent with observations from 
repeat-dose studies in Sprague Dawley rats where the liver-to-serum PFOS 
concentration ratios ranged from 2.5 – 12.2 in Sprague Dawley rats after 4 to 14 
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weeks of dosing (Seacat et al., 2002).   Thus, these data suggest that PFOS is 
preferentially distributed to the liver and may undergo enterohepatic circulation. 
 
There is some evidence that enterohepatic circulation may contribute to the 
preferential distribution of PFSAs to liver.  Male rats were given a single IV dose 
of 14C-labelled PFOS and followed for 21 days during which they were given 
either a basal diet or a diet containing the bile acid sequestrant, cholestyramine 
(Johnson et al., 1984).  Fecal elimination of PFOS was increased approximately 
10-fold, and liver and serum PFOS concentration were reduced by 75% and 85%, 
respectively, in rats given cholestyramine in their diet as compared to rats fed 
basal diet.  In humans, a case study involving a single human subject provided 
evidence that cholestyramine was effective in removing both PFOS and PFHxS 
via fecal elimination (Genuis et al., 2010).  
    
Although previous studies have demonstrated that certain perfluoroalkyl 
carboxylates are substrates of members of the organic anion transporting 
polypeptide (OATP) and the organic anion transporter (OAT) family (Nakagawa 
et al., 2008; Weaver et al., 2010; Yang et al., 2010; Han et al., 2012), interactions 
between PFSAs and transporters might not be limited to OATPs and OATs.  
During the process of enterohepatic circulation of bile salts, it is well-known that 
the two uptake transporters Na+/taurocholate cotransporting polypeptide (NTCP) 
and apical sodium-dependent bile salt transporter (ASBT) play important roles 
(Hagenbuch and Dawson, 2004). NTCP is highly expressed at the basolateral 
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membrane of hepatocytes and mediates the uptake of bile acids into hepatocytes 
in a sodium-dependent manner (Claro da Silva et al., 2013). Beside bile acids, 
other known substrates of NTCP include steroid sulfates such as estrone-3-
sulfate (Schroeder et al., 1998), anti-hyperlipidemic drugs like rosuvastatin (Ho et 
al., 2006), and drug conjugates such as chlorambucil-taurocholate (Kullak-Ublick 
et al., 1997). When bile acids reach the gastrointestinal tract, ASBT localized to 
the brush-border membrane in the terminal ileum reabsorbs the majority of them 
and OSTα/β exports them across the basolateral membrane of enterocytes 
(Ballatori et al., 2005). ASBT is also expressed at the apical membrane of renal 
proximal tubular epithelial cells and at the apical membrane of cholangiocytes. 
Similar to NTCP, the transport by ASBT depends on the sodium gradient across 
the cell membrane. In contrast to NTCP, ASBT has narrow substrate specificity, 
which is restricted to bile acids (Claro da Silva et al., 2013). 
 
Given the evidence that PFOS and PFHxS might undergo enterohepatic 
circulation and given the important role the bile salt transporters play in the 
enterohepatic circulation, we hypothesized that bile salt transporters are involved 
in the disposition of PFSAs. In this study, we investigated the roles of human and 
rat NTCP and ASBT as well as of human OSTα/β in transporting PFBS, PFHxS, 
and PFOS. Initial inhibition studies and uptake experiments indicated the 
potential of the interactions between PFSAs and the transporters. Based on 
these results, additional time dependency and kinetic studies were performed.  
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II. Results 
2.1 Uptake of PFSAs by human and rat hepatocytes 
To determine whether or not sodium-dependent transporters are involved in the 
uptake of PFSAs into hepatocytes, uptake of 50 µM PFBS, PFHxS, and PFOS 
were measured at 2 min using freshly isolated human and rat hepatocytes. First, 
sodium-dependent uptake of [3H]-taurocholate was used to ascertain that the 
isolated hepatocytes were functional (Fig. 3-1). Then, sodium-dependent uptake 
of the three PFSAs were measured in the same batches of hepatocytes. As 
shown in Figure 3-2A, sodium-dependent uptake was observed for all three 
PFSAs in human hepatocytes. Under the experimental conditions used, the 
sodium-dependent uptake (net uptake, black bar) was lowest for PFBS while the 
signal for PFHxS and PFOS was similar and larger. Sodium-dependent uptake 
also was observed in rat hepatocytes for PFBS, PFHxS and PFOS (Fig. 3-2B). 
Uptake was also measured in the presence of 100 µM bromosulfophthalein, a 
known inhibitor of both NTCP and the OATPs. BSP inhibited both sodium-
dependent and sodium-independent uptake of PFBS and to a lesser degree also 













Figure 3-1: TCA uptake by hepatocytes 
Taurocholate uptake mediated by human and rat hepatocytes. Uptake of 30 nM 
[3H]-TCA was measured with freshly isolated human (A) or rat (B) hepatocytes in 
the absence or presence of sodium for 1 min at 37°C. Each bar represents the 
mean ± SD of the uptake of triplicates. The results were corrected for total 














Figure 3-2: PFSA uptake into freshly isolated human (A-C) and rat (D-F) 
hepatocytes 
Uptakes of 50 µM PFBS, PFHxS, and PFOS in the absence or presence of 100 
µM bromosulfophthalein (BSP) was measured in freshly isolated human (HH) 
and rat hepatocytes (RH) at 2 min in the absence (white bars) or presence (gray 
bars) of sodium. Net sodium-dependent uptake (black bars) was calculated by 
subtracting the value of uptake in the absence of sodium from uptake in the 
presence of sodium. Each bar represents the mean ± SD from three independent 
experiments with triplicate determinations. The results were corrected for total 
protein concentration in each well. *p<0.05. 
	     
	  51	  
2.2 Uptake of PFSAs by human and rat NTCP 
To test whether PFSAs would interact with human or rat NTCP, uptake of the 
model substrate [3H]-taurocholate was measured in the absence or presence of 
10 µM PFBS, PFHxS or PFOS. In CHO Flp-in cells stably expressing human 
NTCP, this uptake was inhibited in a chain length-dependent way with PFOS 
inhibiting the strongest, followed by PFHxS and then PFBS (Fig. 3-3A). In 
HEK293 cells transiently expressing rat NTCP, PFHxS showed the strongest 
inhibition of [3H]-taurocholate uptake (50% inhibition) while PFBS and PFOS 














Figure 3-3: Inhibition of 3H-taurocholate uptake mediated by human (A, 
hNTCP) and rat (B, rNTCP) NTCP by PFSAs   
Human NTCP-mediated 30 nM [3H]-taurocholate uptake was measured at 37°C 
for 1 min in the absence (DMSO) or presence of 10 µM PFBS, PFHxS, and 
PFOS using the CHO-hNTCP cell line. Rat NTCP-mediated 30 nM [3H]-
taurocholate uptake was measured at 37°C for 1 min in the absence or presence 
of 10 µM PFBS, PFHxS, and PFOS using HEK293 cells transiently transfected 
with rNTCP. Each bar represents the mean ± SD of triplicate determinations. The 
results were corrected for total protein concentration in each well. *p<0.05 











































































Based on the results of the inhibition experiments that demonstrated interactions 
with all three PFSAs, direct uptakes of PFBS, PFHxS, and PFOS by human and 
rat NTCP were determined and quantified by LC-MS/MS. As shown in Figure 3-
4A, at 10 µM substrate and 1 min incubation, sodium-dependent uptake by 
human NTCP was highest for PFOS, followed by PFHxS and PFBS mirroring the 
chain length-dependent inhibition seen with PFCAs. In contrast, uptake by rat 



















Figure 3-4: Uptake of PFSA by human (A, hNTCP) and rat (B, rNTCP) 
NTCP 
CHO-hNTCP cells or HEK293 cells transiently transfected with rNTCP were used 
to measure the uptake of 10 µM PFBS, PFHxS, and PFOS in the absence (white 
bars) and presence (gray bars) of sodium. Net sodium-dependent uptake (black 
bars) was calculated by subtracting the values of uptake in the absence of 
sodium from uptake in the presence of sodium. Each bar represents the mean ± 
SD from two independent experiments each performed with triplicate 








In order to further characterize the transport by NTCP, uptakes of PFBS, PFHxS 
and PFOS were measured in a time dependent manner at a low (10 µM) as well 
as at a high substrate concentration (200 µM for PFBS and 400 µM for PFHxS 
and PFOS). At the low concentration, the initial linear portion of human NTCP-
mediated transport was different between the three PFSAs (Fig. 3-5A-C) and 
extended up to 60 seconds for PFOS. For rat NTCP the initial linear range was 
between 20 seconds for PFBS (Fig. 3-5D) and 30 seconds for both PFHxS (Fig. 
3-5E) and PFOS (Fig. 3-5F).  At the high substrate concentration, uptake of all 

















Figure 3-5: Time dependent uptake of PFSAs by human (A, B, C; hNTCP) 
and rat (D, E, F; rNTCP) NTCP  
Uptake of 10 µM PFBS (A, D), PFHxS (B, E), and PFOS (C, F) was measured at 
37°C at the indicated time points using CHO-hNTCP cells and HEK293 cells 
transiently transfected with rNTCP in the absence (circles) and presence 
(squares) of sodium. Net sodium-dependent uptake (triangles) was calculated by 
subtracting the value of uptake in the absence of sodium from uptake in the 
presence of sodium. The results were corrected for total protein concentration in 







Based on the results from the time-dependent uptake experiments, all 
concentration-dependent transport measurements for kinetic analysis of PFBS, 
PFHxS and PFOS were determined at 10 seconds. Concentration-dependent net 
sodium-dependent uptake of PFBS, PFHxS and PFOS by human NTCP, and 
PFBS and PFHxS by rat NTCP is shown in Figure 3-6. Kinetic parameters were 
calculated based on the Michaelis-Menten equation and the resulting Km and 
Vmax values are summarized in Table 1.  PFBS was transported by human NTCP 
with the highest affinity (Km value of 39.6 µM) but the lowest Vmax value while both 
PFHxS (Km = 112 µM) and PFOS (Km = 130 µM) had lower affinities and higher 
maximal transport rates. The intrinsic clearance (Vmax/Km) was similarly twice as 
high for the two substrates with the higher Vmax values. With respect to rat NTCP, 
although PFBS was transported with a higher affinity (Km =76.2 µM) than PFHxS 
(Km=294 µM) the difference in the Vmax values resulted in equal intrinsic 
clearances for both compounds (Table 3-1).  The kinetic parameters of PFOS by 











Figure 3-6: Kinetics of human (A, B, C) and rat (D, E) NTCP-mediated 
transport of PFBS (A, D), PFHxS (B, E), and PFOS (C)  
Uptake of increasing concentrations of PFBS, PFHxS, and PFOS was measured 
within the initial linear range of transport using CHO-hNTCP cells (A, B, C) and 
HEK293 cells transiently transfected with rNTCP (D, E). Net uptake was 
calculated by subtracting the values of uptake in the absence of sodium from 
uptake in the presence of sodium and was corrected for total protein 
concentration. Resulting data were fitted to the Michaelis-Menten equation to 
obtain Km and Vmax values (Table 3-1). Each point represents the mean ± SD 






Table 3-1: Kinetic parameters of PFBS, PFHxS and PFOS transport 
mediated by human or rat NTCP 





PFBS 39.6±8.2 3.7±0.3 0.1±0.02 
PFHxS 112±32.9 23.2±3.0 0.2±0.07 
PFOS 130 ±32.9 30.7±3.2 0.2±0.06 
rNTCP 
PFBS 76.2±23.6 2.2±0.3 0.03±0.01 














2.3 Inhibition of human MRP2, BCRP and BSEP transport by PFSAs 
To determine whether PFSAs interact with efflux transporters in the hepatocytes, 
the transport of model substrates by human MRP2, BCRP and BSEP in Sf9 
vesicles was measured in the absence or presence of 10 µM or 100 µM PFBS, 
PFHxS or PFOS. Transport of CDCF by human MRP2 was not affected by PFBS 
(Fig. 3-7A). At 10 µM, only PFOS inhibited CDCF transport, while at 100 µM, 
both PFHxS and PFOS showed inhibition, with PFOS inhibiting transport by over 
80% (Fig. 3-7A). Transport of [3H]-estrone-3-sulfate mediated by human BCRP 
was decreased in the presence of all three PFSAs, however, only the inhibition 
by 100 µM PFHxS was significant (Fig. 3-7B). In addition, BSEP-mediated 
transport of [3H]-taurocholate was only inhibited by 100 µM PFOS but not by any 














Figure 3-7: Inhibition of human MRP2 (A), BCRP (B) and BSEP (C) 
transport by PFSAs  
Transport of 5 µM CDCF, 0.01 µM [3H]-estrone-3-sulfate or 0.5 µM [3H]-
taurocholate by human MRP2, BCRP and BSEP vesicles were measured with or 
without 10 µM (Black bar) or 100 µM (white bar) PFBS, PFHxS and PFOS. Each 




























































2.4 Transport of PFSAs by human and rat ASBT 
ASBT is another sodium-dependent transporter belonging to the same gene 
family as NTCP. It is normally expressed at the apical membrane of ileal 
enterocytes, cholangiocytes and renal proximal tubular epithelial cells and 
transports bile acids in a sodium-dependent way. In HEK293 cells transiently 
expressing human or rat ASBT, uptake of 10 µM PFBS, PFHxS or PFOS was 
measured at 1 minute in the absence or presence of sodium. Sodium-dependent 
uptake was only observed for PFOS by human ASBT (Fig. 3-8A) while none of 
the three PFSAs were transported by rat ASBT (Fig. 3-8B). Human and rat ASBT 
function was confirmed by measuring sodium-dependent transport of the model 
substrate [3H]-taurocholate (Fig. 3-9). 
 
Time-dependent uptake was performed for human ASBT-mediated PFOS in 
order to further characterize its kinetics. Uptake was linear up to 2 minutes at 
both the low (10 µM) and high (400 µM) PFOS concentration (Fig. 3-8C and Fig. 
3-8D). However, the kinetic parameters of PFOS transport could not be 


















Figure 3-8: Uptake of PFSAs by human (A, C, D) and rat (B) ASBT   
HEK293 cells transiently transfected with hASBT (A) or rASBT (B) were used to 
measure uptake of 10 µM PFBS, PFHxS, and PFOS in the absence (white bars) 
or presence (gray bars) of sodium for 2 minutes. Net sodium-dependent uptake 
(black bars) was calculated by subtracting the values of uptake in the absence of 
sodium from uptake in the presence of sodium. Each bar represents the mean ± 
SD of triplicates from two independent experiments. (C, D) Uptake of 10 µM 
PFOS was measured at 37°C for the indicated time points by HEK293 cells 
transiently transfected with hASBT in the absence (circles) or presence (squares) 
of sodium. Net sodium-dependent uptake (triangles) was calculated by 
subtracting the values of uptake in the absence of sodium from uptake in the 
presence of sodium. The results were corrected for total protein concentration in 













Figure 3-9: Taurocholate uptake mediated by human and rat ASBT  
Using HEK293 cells transiently transfected with human (A) or rat (B) ASBT cDNA, 
uptake of 30 nM [3H]-TCA was measured in the absence or presence of sodium 
for 1 min at 37°C. Each bar represents the mean ± SD of the uptake of triplicates. 











2.5 Transport of PFSAs by human OSTα/β 
Human OSTα/β is expressed at the basolateral membrane of enterocytes to 
mediate the efflux of bile acids. Since it can transport bi-directionally depending 
on the concentration gradient of substrates, uptake of 10 µM PFSAs was 
measured at 2 and 10 min after establishing the proper function of OSTα/β (Fig. 
3-10). At both time points, uptake of all three PFSAs was higher in human 
OSTα/β transfected HEK293 cells than in empty vector transfected cells and net 
uptake was higher at 10 min as compare to 2 min (Fig. 3-11).   
                      
Figure 3-10: Human OSTα/β-mediated transport of TCA  
Using HEK293 cells transiently transfected with human OSTα and OSTβ cDNA 
containing plasmid, uptake of 30 nM [3H]-TCA was measured for 2 min at 37°C. 
Each bar represents the mean ± SD of the uptake of triplicates. The results were 






Figure 3-11: Uptake of PFSAs by human OSTα/β  
HEK293 cells transiently transfected with hOSTα/β (gray bars) or empty vector 
pcDNA5/FRT (white bars) were used to measure uptake of 10 µM PFBS (A), 
PFHxS (B) or PFOS (C) at 2 min and 10 min. Net uptake (black bars) was 
calculated by subtracting the values of uptake in empty vector transfected cells 
from uptake in the hOSTα/β transfected cells. The results were corrected for total 
protein concentration in each well.  Each bar represents the mean ± SD of 










In this chapter, we have demonstrated that uptake of PFSAs into human and rat 
hepatocytes is mediated by sodium-dependent and sodium-independent 
mechanisms. Furthermore, we showed that all three PFSAs, PFBS, PFHxS and 
PFOS, are substrates for human and rat NTCP. Carrier-mediated uptake by rat 
hepatocytes was reported previously for PFOA and bromosulphophthalein (BSP), 
an inhibitor of OATPs and NTCP, can inhibit this transport (Han et al., 2008). 
However, specific transporters were not identified until now. In addition to NTCP, 
we also demonstrated that human ASBT can mediate the uptake of PFOS. To 
the best of our knowledge, this is the first time that sodium-dependent transport 
is reported for PFASs. Furthermore, human OSTα/β was able to transport all 
three PFSAs. 
 
We used BSP inhibition to get an idea whether the sodium-independent OATPs 
or the sodium-dependent NTCP would be the major transport system for the 
uptake of PFSAs into hepatocytes. The fact that sodium-independent uptake of 
PFOS was hardly inhibited by BSP (Fig. 3-2) suggests that NTCP is the major 
uptake transporter and that OATPs, at most, play a minor role. The shorter chain 
PFBS and PFHxS are probably transported by both types of transporters but 
again, NTCP seems to be the major carrier given the minor inhibition of the 
sodium-independent uptake (Fig. 3-2). 
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Fenestration of sinusoids in combination with specific transporters in the 
sinusoidal membrane of hepatocytes allows excretion of numerous protein bound 
xenobiotics by the liver. These fenestrae allow the protein-bound compounds to 
get into close proximity with the uptake transporters in hepatocytes while protein 
binding prevents their glomerular filtration in the kidneys. Both PFOS and PFHxS 
are highly protein-bound in the plasma, predominately to albumin (Kerstner-
Wood, 2004; Butenhoff et al., 2012), and given that NTCP can transport these 
PFSAs and is abundantly expressed in the sinusoidal membrane, could be the 
major mechanism for the previously reported preferential liver accumulation of 
these compounds (Maestri et al., 2006; Karrman et al., 2010).  
 
In humans, biliary excretion has been suggested as the main route of elimination 
for PFOS and has been estimated to be 200-fold higher than urinary excretion 
(Harada et al., 2007). The estimated reabsorption rates are 97 percent and 95 
percent in humans and rats, respectively, very comparable between the two 
species (Harada et al., 2007). Our findings that in particular PFOS but to a lesser 
degree also PFHxS were able to inhibit MRP2, BCRP and BSEP, three of the 
ABC transporters expressed in the canalicular membrane of human hepatocytes, 
suggests that these transporters are likely candidates for canalicular secretion of 
PFOS and PFHxS. We would like to emphasize that inhibition does not 
necessarily mean that the inhibitors are substrates of the transporters they inhibit 
and as a consequence these three transporters should be tested in the future 
whether they directly mediate transport of PFOS and PFHxS. 
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We demonstrated that human ASBT can transport PFOS when expressed in 
HEK293 cells. Assuming that human ASBT can transport PFOS also in vivo 
would suggest that PFOS is absorbed in the intestine preferentially compared to 
other PFSAs. The relative high unspecific background seen in our data indicates 
that passive diffusion of PFOS probably plays an important role as well. We had 
preliminary data that additional transporters expressed in the small intestine like 
human OATP2B1 (Drozdzik et al., 2014) and rat OATP1A5 (Walters et al., 2000b) 
could play a role in the reabsorption of PFSAs, especially in the case of PFHxS 
and PFBS which were not transported by rat ASBT. The detailed functional 
characterization of these transporters will need to be presented in the following 
chapter of this dissertation. 
 
In addition to enterocytes, ASBT is also expressed in the epithelial cells lining the 
bile duct where it samples biliary contents for signaling to the hepatocytes and is 
part of the cholehepatic shunt pathway (Benedetti et al., 1997; Meier and Stieger, 
2002; Xia et al., 2006). Due to the transport by ASBT, cholehepatic shunting of 
PFOS might be an additional critical component for its retention in human liver. 
Serum albumin bound PFOS likely limits its glomerular filtration (Butenhoff et al., 
2012). In addition, ASBT present in the brush border membrane of proximal 
tubular epithelial cells (Hagenbuch and Dawson, 2004) could reabsorb the limited 
amount of unbound PFOS filtered, keeping the urinary excretion at its very low 
levels.  
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Although we showed that PFBS is a substrate of both human and rat NTCP, the 
human serum elimination half-life has been estimated to be around 26 days and 
urine was shown to be the dominant route of elimination (Olsen et al., 2009). This 
significant urinary excretion could be due to glomerular filtration or due to 
transporters of the OAT family that are expressed in the kidney (OAT1 and 
OAT3). Because these carriers are involved in the transport of the shorter chain 
PFCAs (Weaver et al., 2010) they are also likely candidates for PFBS secretion 
(see Chapter 5). 
 
It is well accepted that human NTCP transports, in addition to bile acids, other 
endo- and xenobiotics, including some of the statins (Bi et al., 2013). Even 
though ASBT is a bile acid cotransporter closely related to NTCP, to date, known 
substrates of ASBT have been restricted to bile acids (Hagenbuch and Dawson, 
2004; Dawson, 2011). Thus, the identification of PFOS as an ASBT substrate 
represents a very novel finding. This raises the possibility that other compounds 
similar to PFOS might be substrates of ASBT.  
 
In conclusion, our studies reveal that PFBS, PFHxS, and PFOS are substrates 
for the sodium-dependent liver transporter NTCP in humans and rats, and that 
human ASBT transports PFOS. The three ABC transporters MRP2, BCRP and 
BSEP are inhibited in particular by PFOS, and human OSTα/β can transport all 
three PFSAs. Thus, the combined action of the hepatic NTCP and ABC 
transporters, together with the intestinal ASBT and OSTα/β likely facilitates the 
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enterohepatic circulation of PFHxS and PFOS. In addition, ASBT expressed in 
cholangiocytes possibly contributes to cholehepatic shunting of PFOS. Both 
pathways together enhance liver accumulation and likely contribute to the long 



































Organic anion transporting polypeptides contribute to the 
disposition of perfluoroalkyl acids in humans and rats 
 
I. Introduction 
Perfluoroalkyl acids (PFAAs), including perfluoroalkyl carboxylates (PFCAs) and 
perfluoroalkyl sulfonates (PFSAs), are fluorinated fatty acid-like chemicals, which 
are widely used in commerce since the 1950s (Prevedouros et al., 2006; Buck et 
al., 2011). Certain PFAAs have received attention in recent years, because they 
are resistant to environmental degradation and frequently detectable in human 
blood (Fromme et al., 2009; Kato et al., 2011; Zhao et al., 2012).  The presence 
of certain PFAAs in human blood may, in part, be due to their retention in the 
body through renal proximal tubule reabsorption and enterohepatic circulation 
after exposures from various environmental sources (Andersen et al., 2008).   
 
There are several differences in the elimination kinetics of PFAAs depending on 
species, genders within species, and number of carbons in the perfluoroalkyl 
chain.  In particular, the PFSAs, perfluorooctane sulfonate (PFOS) and 
perfluorohexane sulfonate (PFHxS) as well as the PFCA, perfluorooctanoate 
(PFOA), have serum elimination half-lives in humans of several years (Olsen et 
al., 2007; Bartell et al., 2010).  Pharmacokinetic studies on these three PFAAs in 
non-humans have demonstrated considerable variation in serum elimination half-
lives between species (Hundley et al., 2006; Chang et al., 2012; Sundstrom et al., 
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2012) and, in some cases, between genders within species (Hundley et al., 2006; 
Sundstrom et al., 2012), but are generally much shorter than the reported human 
serum elimination half-lives.  For example, for PFOS, the reported serum 
elimination half-lives in rats and mice were on the order of 1–2 months and, in 
monkeys, approximated 4 months (Chang et al., 2012), as opposed to several 
years in humans (Olsen et al., 2007).  In another example, the serum elimination 
half-life of PFOA in female rats is a few hours versus several days in male rats 
(Kennedy et al., 2004; Hundley et al., 2006).        
 
In addition to these species and gender differences in elimination for certain 
PFAAs, PFAAs with fewer carbons in the perfluoroalkyl chain tend to have 
shorter serum elimination half-lives than their longer homologs (Lau, 2015).  For 
example, the serum elimination half-lives in humans for perfluorobutane 
sulfonate (PFBS) and perfluorohexanoate (PFHxA) are approximately one month 
(Olsen et al., 2009; Russell et al., 2013) versus several years for PFOS and 
PFOA (Olsen et al., 2007; Bartell et al., 2010).        
 
In attempting to explain these kinetic differences, attention has focused on the 
role of membrane transporters.  Kudo et al. (Kudo et al., 2002)  first provided 
experimental support for sex hormone-mediated expression of organic anion 
transporters (OATs) in rat kidneys to explain male and female differences in 
clearance of PFOA, and suggested a possible role for organic anion transporting 
polypeptide 1A1 (OATP1A1) in proximal tubule reabsorption of PFOA in male 
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rats.  Subsequent experimental and modelling studies have provided substantial 
additional support for role of transporter-mediated renal proximal tubule 
reabsorption in the differential retention of PFOA (Han et al., 2003; Andersen et 
al., 2006; Katakura et al., 2007a; Yang et al., 2009; Weaver et al., 2010; 
Loccisano et al., 2011).  At this point in time, it is fair to conclude that renal 
transporters play a key role in defining the kinetic characteristics of PFAAs. 
 
While there has been a fair amount of effort to investigate renal proximal tubule 
transporters, fewer studies have focused on the role of enterohepatic circulation, 
which likely is important based on the observation that PFAAs tend to 
preferentially distribute to liver and serum (Kemper, 2003; Kudo et al., 2007; 
Bogdanska et al., 2011; Chang et al., 2012; Sundstrom et al., 2012).  The 
available experimental evidence supports the role of enterohepatic circulation as 
a possible contributing factor to the retention of PFHxS and PFOS in humans 
(Genuis et al., 2010; Genuis et al., 2013), and PFOS and PFOA in rats (Johnson 
et al., 1984).  The latter studies investigated the effect of the binding agent, 
cholestyramine, in facilitating the gastrointestinal clearance of PFAAs.   
 
In Chapter 3, we demonstrated that the uptake of PFBS, PFHxS and PFOS into 
freshly isolated human and rat hepatocytes was sodium-dependent and 
Na+/taurocholate cotransporting polypeptide (NTCP), a sodium-dependent bile 
salt transporter expressed at the sinusoidal membrane of hepatocytes, was the 
responsible transporter (Zhao et al., 2015a). We have also shown that 
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bromosulfophthalein inhibits the sodium-independent portion of PFBS and 
PFHxS uptake into hepatocytes, indicating the involvement of sodium-
independent transporters. At the hepatocyte sinusoidal membrane (Fig. 4-1), 
there are several organic anion transporting polypeptides (OATPs) expressed, 
including hOATP1B1, hOATP1B3 and hOATP2B1 in humans (Hsiang et al., 
1999; König et al., 2000; Tamai et al., 2000; Roth et al., 2012) and rOATP1A1, 
rOATP1A4, rOATP1B2 and rOATP2B1 in rats (Bergwerk et al., 1996b; Noé et al., 
1997; Kakyo et al., 1999; Nishio et al., 2000; Cattori et al., 2001). These are 
sodium-independent transporters that mediate the uptake of endogenous and 
exogenous compounds, such as taurocholate, estrone-3-sulfate, bilirubin and 
numerous drugs including statins (Hagenbuch and Stieger, 2013).  
  
In addition to the liver, we also demonstrated that human apical sodium-
dependent bile salt transporter (ASBT), but not rat ASBT, expressed at the apical 
membrane of the small intestine can transport PFOS, contributing to the 
intestinal reabsorption of PFOS in humans. However, transporters involved in the 
enterohepatic circulation of PFHxS and PFOS in rats and PFHxS in humans 
have not been identified. Candidate transporters in the human intestine are 
hOATP1A2 and hOATP2B1, but, based on recent proteomics work, only 
hOATP2B1 should be considered as an intestinal transporter (Fig.4-1) (Drozdzik 
et al., 2014). In rats, the corresponding transporters are rOATP1A5 and 
rOATP2B1 (Fig. 4-1).  All three transporters are involved in the intestinal 
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absorption of several drugs including pravastatin, pitavastatin and fexofenadine 




Figure 4-1: Expression of human and rat OATPs in hepatocytes and 
enterocytes 






PFOA is a substrate of OATPs and OATs. In rats, rOATP1A1, rOAT1, rOAT3 
and in humans, hOAT1, hOAT3, hOAT4 mediate the transport of PFOA 
(Katakura et al., 2007a; Nakagawa et al., 2008; Nakagawa et al., 2009; Yang et 
al., 2009). Consistently, our laboratory previously has shown chain-length 
dependent transport of PFCAs with 7 to 10 carbons by rOAT1, rOAT3 and 
rOATP1A1 (Weaver et al., 2010). Because rOATP1A1 is expressed at a higher 
level at the apical membrane of proximal tubules in male rats than in female rats 
(Lu et al., 1996) and seems to be involved in the reabsorption of PFOA, 
rOATP1A1-mediated reabsorption of PFOA is most likely the main mechanism 
for the longer half-life observed in male rats as opposed to females, as first 
speculated by Kudo et al (Kudo et al., 2002). 
 
Based on these combined previous findings, we hypothesized that OATPs 
expressed in hepatocytes and in enterocytes can transport PFAAs and can 
contribute to the enterohepatic circulation and hepatic accumulation in humans 
and rats. Therefore, in the present study, we characterized the transport of PFBS, 
PFHxS, and PFOS and PFCAs with 7 to 10 carbons by the three human 
transporters hOATP1B1, hOATP1B3, hOATP2B1, and the transport of PFBS, 





2.1 Uptake of PFSAs by human OATP1B1 and OATP1B3 
To determine whether PFSAs are substrates of the liver-specific transporters 
hOATP1B1 and hOATP1B3, uptake of 10 µM PFBS, PFHxS and PFOS was 
measured for 1 min using CHO cells stably expressing hOATP1B1 (Fig. 4-2A, B) 
or hOATP1B3 (Fig. 4-2C, D).   The results demonstrate that PFBS, PFHxS and 
PFOS are substrates of both hOATP1B1 and hOATP1B3. Net uptake 
(transporter-mediated uptake) of PFHxS and PFOS was higher than of PFBS, 
while the signal-to-noise ratio for PFOS was lower than for the other two. Uptake 
was comparable between hOATP1B1 and hOATP1B3 except that for PFBS 















Figure 4-2: Uptake of PFSAs by hOATP1B1 (A, B) and hOATP1B3 (C, D)  
CHO wild-type (white bars) or CHO cells stably expressing hOATP1B1 or 
hOATP1B3 (gray bars) were used to measure the uptake of 10 µM PFBS (A, C), 
PFHxS (B, D), and PFOS (B, D) for 1 min at 37°C. Net uptake (black bars) was 
calculated by subtracting the values of uptake mediated by wild-type cells from 
uptake mediated by transporter-expressing cells. Each bar represents the mean 
± SD of triplicates from two independent experiments each performed with 
triplicate determinations. The results were corrected for total protein 




To further characterize the transport by hOATP1B1 and hOATP1B3, time-
dependent uptake of PFBS, PFHxS and PFOS was measured at low (10 µM) 
and high (400 µM for PFBS and PFHxS, 200 µM for PFOS) substrate 
concentrations (Table 4-1). The initial linear range of hOATP1B1-mediated 
uptake of PFBS, PFHxS and PFOS was 2 min at low concentrations and 1 min at 
high concentrations. At low concentrations, hOATP1B3-mediated uptake of 
PFBS, PFHxS, and PFOS was linear up to 1, 5 and 2 min, respectively. At high 
concentrations, the initial linear range was 1, 2 and 2 min, respectively (Table 4-
1). Based on these time-dependent uptake results, kinetics were performed at 40 
sec for PFBS and PFHxS, and at 1.5 min for PFOS and the results are shown in 
Fig. 4-3A to 4-3F. The kinetic parameters were calculated based on the 
Michaelis-Menten equation and are summarized in Table 4-2. Each of the given 
PFSAs was transported with a similar affinity (Km values) by the two OATPs. 
PFOS had the highest affinity (23 µM for hOATP1B1 and 32 µM for hOATP1B3) 
followed by PFBS (80 µM for hOATP1B1 and 63 µM for hOATP1B3) and PFHxS 
(101 µM for hOATP1B1 and 86 µM for hOATP1B3), respectively. In terms of 
capacity (Vmax values) PFHxS was transported with the highest capacity (2.1 
nmol/mg protein*min-1 for hOATP1B1 and 2.4 nmol/mg protein*min-1 for 
hOATP1B3), followed by PFOS (0.8 nmol/mg protein*min-1 for hOATP1B1 and 
1.0 nmol/mg protein*min-1 for hOATP1B3) and PFBS (0.2 nmol/mg protein*min-1 
for both hOATP1B1 and hOATP1B3), respectively. Dividing the Vmax by the Km 
value yields the transport efficiency (or transporter clearance) and suggested that 
PFHxS and PFOS are transported about tenfold more efficiently than PFBS 
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(Table 4-2), correlating with the longer serum elimination half-lives of PFHxS and 




Table 4-1: Summary of initial linear ranges of human and rat OATP-
mediated uptake of PFBS, PFHxS, and PFOS 
  Low concentration   High concentration  
Transporter  Initial Linear Range (min)   Initial Linear Range (min)  
 PFBS PFHxS PFOS PFBS PFHxS PFOS 
 10 µM 10 µM 10 µM 400 µM 400 µM 400 µM 
hOATP1B1 2 2 2 1 1 11) 
hOATP1B3 1 5 2 1 2 21) 
hOATP2B1 2 1 5 1 1 1 
rOATP1A1 nd2) 5 5 nd2) 5 5 
rOATP1A5 1 10 10 2 1 5 
 









Figure 4-3: Kinetics of hOATP1B1- (A, B, C) and hOATP1B3- (D, E, F) 
mediated transport of PFBS (A, D), PFHxS (B, E), and PFOS (C, F)  
CHO wild-type, CHO-hOATP1B1 and hOATP1B3 cells were used to measure 
the uptake (at 40 seconds for PFBS and PFHxS, and 90 seconds for PFOS) of 
increasing concentrations of PFBS, PFHxS and PFOS. Net uptake was 
calculated by subtracting the values of uptake mediated by wild-type cells from 
uptake mediated by transporter-expressing cells. Resulting data were fitted to the 
Michaelis-Menten equation to obtain Km and Vmax values (Table 4-2). The results 
were corrected for total protein concentration in each well. Each point represents 














Table 4-2: Kinetic parameters of PFBS, PFHxS, and PFOS transport 
mediated by human OATP1B1, OATP1B3 and OATP2B1 





PFBS 79.9±46.6 0.2±0.06 2.5 
PFHxS 101±32.1 2.1±0.3 21 
PFOS 23.1±5.9 0.8±0.07 35 
hOATP1B3 
PFBS 62.5±36.7 0.2±0.07 3.2 
PFHxS 85.6±23.5 2.4±0.3 28 
PFOS 32.1±18.9 1.0±0.2 31 
hOATP2B1 
PFBS 122±57.1 0.6±0.1 4.9 
PFHxS 53.1±18.9 2.0±0.2 38 











2.2 Uptake of PFSAs by human OATP2B1 
In addition to hOATP1B1 and hOATP1B3, hOATP2B1 is also expressed at the 
basolateral membrane of hepatocytes and appears to be the major multispecific 
OATP expressed at the apical membrane of human enterocytes. To determine 
whether hOATP2B1 can transport PFSAs, uptake of 10 µM PFBS, PFHxS and 
PFOS was measured at 2 min using CHO Flp-in cells stably expressing 
hOATP2B1 (Fig. 4-4A, B). Net transporter-mediated uptake of PFOS was the 

















Figure 4-4: Uptake of PFSAs by hOATP2B1 
CHO Flp-in cells transfected with pcDNA5/FRT (EV) or stably expressing 
hOATP2B1 were used to measure the uptake of PFBS (A, C), PFHxS (B, D), and 
PFOS (B, F). A, B） Uptake of 10 µM PFBS, PFHxS and PFOS was determined 
at 37 °C for 2 min. Net uptake (black bars) was calculated by subtracting the 
values of uptake mediated by CHO Flp-In EV cells from uptake mediated by 
transporter-expressing cells. C, D, E) Uptake of increasing concentrations of 
PFBS, PFHxS and PFOS was determined at 37 °C for 1 min. Net uptake was 
calculated by subtracting the values of uptake mediated by Flp-In EV cells from 
uptake mediated by transporter-expressing cells. Resulting data were fitted to the 
Michaelis-Menten equation to obtain Km and Vmax values (Table 4-2). Each point 
represents the mean ± SD from three independent experiments performed in 












Next, time-dependent uptake of PFBS, PFHxS and PFOS was measured at low 
(10 µM) and high (400 µM) substrate concentrations to determine the initial linear 
range (Table 4-1). At low substrate concentrations, hOATP2B1-mediated uptake 
of PFBS, PFHxS and PFOS was linear up to 2, 1 and 5 min, respectively. At high 
substrate concentrations, uptake for all three substrates was linear only for 1 min. 
Therefore, concentration-dependent uptake of all three PFSAs was measured at 
1 min, and the results are summarized in Fig.4-4C to 4-4E. After correcting for 
empty-vector control cells the data were fitted using non-linear regression 
analysis to the Michaelis-Menten equation, and the calculated kinetic parameters 
(Km and Vmax) are shown in (Table 4-2). PFOS and PFHxS were transported by 
hOATP2B1 with higher affinity (Km = 48 and 53 µM, respectively) than PFBS (122 
µM). However, bigger differences were seen for the respective Vmax values. 
Transport of PFOS had the largest capacity (4.7 nmol/mg protein*min-1) followed 
by PFHxS (2.0 nmol/mg protein*min-1) and PFBS (0.6 nmol/mg protein*min-1). As 
a consequence, transport efficiency for PFOS was twice as high as for PFHxS 
and even twenty times higher than for PFBS (Table 4-2). Again, these numbers 
correlated well with the longer serum elimination half-lives for PFHxS and PFOS 
as compared to PFBS.  
 
Previous studies demonstrated that transport by hOATP2B1 is pH-dependent 
(Nozawa et al., 2004). However, no significant difference was observed for the 
transport of the three PFSAs by hOATP2B1 when uptake was measured at pH 
7.4 or pH 5.5 (data not shown). 
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2.3 Uptake of PFSAs by rat liver OATPs 
In rats, rOATP1A1, rOATP1A4, rOATP1B2, and rOATP2B1 are all expressed at 
the basolateral membrane of hepatocytes. To determine which of these OATPs 
are involved in the liver accumulation of PFSAs in rats, uptake of 10 µM PFBS, 
PFHxS, and PFOS was measured in HEK293 cells transiently expressing these 
transporters individually. As shown in Figure 4-5A and 4-5B, rOATP1A1 could 
transport all three PFSAs. Because the signals were well above the empty vector 
transfected cells for PFHxS and PFOS, kinetics were performed at a 5 min 
uptake point (within the initial linear range, Table 4-1) and the results are 
summarized in Figure 4-5C, 4-5D and in Table 4-3. The capacity for PFHxS and 
PFOS transport was similar (1.0 nmol/mg protein*min-1 for PFHxS and 0.7 
nmol/mg protein*min-1 for PFOS), but the affinity for PFOS (Km = 37 µM) was 












      
Figure 4-5: Uptake of PFSAs by rOATP1A1 
HEK293 cells transiently transfected with empty vector pExpress-1 (pE) or 
rOATP1A1 were used to measure the uptake of PFBS (A), PFHxS (B, C), and 
PFOS (B, D). A, B）Uptake of 10 µM PFBS, PFHxS and PFOS was measured at 
37 °C for 1 min. Net uptake (black bars) was calculated by subtracting the values 
of uptake mediated by pE transfected HEK293 cells from uptake mediated by 
transporter-expressing cells. C, D) Uptake of increasing concentrations of PFHxS 
and PFOS was determined at 37 °C for 5 min. Net uptake was calculated by 
subtracting the values of uptake mediated by cells transfected with pE from 
uptake mediated by transporter-expressing cells. Resulting data were fitted to the 
Michaelis-Menten equation to obtain Km and Vmax values (Table 4-3). Each point 
represents the mean ± SD from three independent experiments performed in 
triplicate. The results were corrected for total protein concentration in each well. 
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Table 4-3: Kinetic parameters of PFBS, PFHxS and PFOS transport 
mediated by rat OATP1A1 and OATP1A5 





PFHxS 256±68.9 1.0±0.1 3.9 
PFOS 36.9±18.7 0.7±0.1 19 
rOATP1A5 
PFBS 117±41.0 0.2±0.04 1.7 
PFHxS 160±122 1.2±0.5 7.5 















Results for the uptake of 10 µM PFBS, PFHxS and PFOS at 1 min and 5 min by 
rOATP1B2 and rOATP2B1 are shown in Fig. 4-6. All three PFAAs are 
transported by both transporters, and the signals were comparable between 
rOATP1B2 and rOATP2B1. For both OATPs, the net transporter-mediated 
uptake of PFBS was about tenfold lower than uptake of PFHxS and PFOS. 
However, signal to background ratios were not high enough to perform kinetic 
analyses. For the fourth rat OATP, rOATP1A4, no net transporter-mediated 











Figure 4-6: Uptake of PFSAs by rOATP1B2 (A, C, E) and rOATP2B1 (B, D, 
F) 
HEK293 cells transiently transfected with empty vector pcDNA5/FRT (white bars), 
and rOATP1B2 or rOATP2B1 (grey bars) were used to measure the uptake of 10 
µM PFBS, PFHxS or PFOS for 1 min and 5 min at 37°C. Net uptake (black bars) 
was calculated by subtracting the values of uptake mediated by empty vector 
transfected cells from uptake mediated by transporter-expressing cells. Each bar 
represents the mean ± SD from three independent experiments each performed 
with triplicate determinations. The results were corrected for total protein 













2.4 Uptake of PFSAs by rat OATP1A5 
Besides rOATP2B1, rOATP1A5 is also expressed on the apical membrane of 
enterocytes (Walters et al., 2000a). To test whether rOATP1A5 could also 
contribute to the disposition (absorption) of PFSAs, HEK293 cells transiently 
expressing rOATP1A5 were used to measure the uptake of 10 µM PFBS, PFHxS 
or PFOS. As summarized in Figures 4-7A and 4-7B, rOATP1A5 transports all 
three PFSAs. Net rOATP1A5-mediated uptake was highest for PFOS, followed 
by PFHxS and PFBS.  
 
In order to perform kinetics analyses, first, time-dependent uptake was measured 
at low (10 µM)  and high (400 µM) substrate concentrations (Table 4-1). Based 
on these experiments, the concentration-dependent uptake of PFBS and PFHxS 
was measured at 1 min, while for PFOS, 5 min were used. As shown in Table 4, 
PFOS was transported with the highest affinity (Km = 55 µM), followed by PFBS 
(Km = 117 µM) and by PFHxS (Km = 160 µM). In terms of capacity, PFHxS and 
PFOS were transported with the same Vmax value (1.2 nmol/mg protein*min-1), 
while PFBS was transported with a sixfold lower capacity. As a consequence, 
transporter efficiency for PFOS was threefold higher than for PFHxS and 










Figure 4-7: Uptake of PFSAs by rOATP1A5  
HEK293 cells transiently transfected with empty pSport6 vector (EV) or 
rOATP1A5 were used to measure the uptake of PFBS (A, C), PFHxS (B, D), and 
PFOS (B, E). A,B）Uptake of 10 µM PFBS, PFHxS and PFOS was measured at 
37 °C for 1 min. Net uptake (black bars) was calculated by subtracting the values 
of uptake mediated by EV transfected HEK293 cells from uptake mediated by 
transporter-expressing cells. C, D, E) Uptake of increasing concentrations of 
PFBS, PFHxS and PFOS was measured at 37 °C for 1 (PFBS and PFHxS) or 5 
min (PFOS). Net uptake was calculated by subtracting the values of uptake 
mediated by EV transfected cells from uptake mediated by transporter-
expressing cells. Resulting data were fitted to the Michaelis-Menten equation to 
obtain Km and Vmax values (Table 4-3). Each point represents the mean ± SD 
from three independent experiments performed in triplicates. The results were 








2.5 Uptake of perfluoroalkyl carboxylates by human OATP1B1, OATP1B3 
and OATP2B1 
To test which OATPs can contribute to the transport of perfluoroheptanoate (C7), 
perfluorooctanoate (C8), perfluorononanoate (C9), and perfluorodecanoate (C10) 
into human hepatocytes, 1 min uptake of 10 µM of C7 to C10 was measured in 
CHO cells stably expressing hOATP1B1, hOATP1B3 or hOATP2B1. The results 
are summarized in Fig. 4-8 and demonstrate that C8 is a substrate of all three 
human OATPs that are expressed in hepatocytes. C10 is transported by 
hOATP1B1 and hOATP1B3 while C7 and C9 are only transported by hOATP1B1. 
Transport mediated by hOATP1B3 was highest and similar for C8 and C10. In 
contrast, hOATP1B1-mediated transport increased with the chain-length from C7 
to C9, while uptake of C10 was lower. Uptake of C8 mediated by hOATP2B1 was 






















Figure 4-8: Uptake of PFCAs by hOATP1B1 (A), hOATP1B3 (B) and 
hOATP2B1 (C) 
CHO wild-type cells (white bars) or CHO cells stably expressing hOATP1B1, 
hOATP1B3 or hOATP2B1 (gray bars) were used to measure the uptake of 10 µM 
C7-C10 PFCA for 1 min at 37°C. Net uptake (black bars) was calculated by 
subtracting the values of uptake mediated by wild-type cells from uptake 
mediated by transporter-expressing cells. Each bar represents the mean ± SD 
from two independent experiments each performed with triplicate determinations. 








In this chapter, we have demonstrated that PFAAs, including PFBS, PFHxS and 
PFOS are substrates of human hOATP1B1, hOATP1B3, hOATP2B1 and rat 
rOATP1A1, rOATP1B2, rOATP2B1 and rOATP1A5. Furthermore, we showed 
that hOATP1B1, hOATP1B3 and hOATP2B1 can transport certain PFCAs with 7 
to 10 carbons.  
 
In the studies presented in Chapter 3, we demonstrated that bromosulfophthalein 
inhibits sodium-independent uptake of PFBS and PFHxS into human and rat 
hepatocytes, while sodium-independent uptake of PFOS was not inhibited (Zhao 
et al., 2015a). Those results suggested that, besides the sodium-dependent 
portion mediated by hNTCP or rNTCP, a sodium-independent portion of uptake 
at least for PFHxS and PFBS exists. Our findings reported in this study clearly 
demonstrate that the human hOATP1B1, hOATP1B3, and hOATP2B1, as well as 
the rat rOATP1A1, rOATP1B2, and rOATP2B1, can transport PFBS and PFHxS 
and therefore likely contribute to the sodium-independent uptake into human and 
rat hepatocytes. Although there was no inhibition of sodium-independent PFOS 
uptake by bromosulfophthalein, direct uptake measurements showed that all 
three human OATPs were able to transport PFOS. Comparing the calculated 
transport efficiencies (Vmax/Km values) for the individual OATPs with respect to 
the three different PFSAs, our data clearly indicated that PFBS was transported 
with the lowest efficiency by all three human OATPs (Table 4-1). Transport 
efficiencies for PFHxS and PFOS were almost ten fold higher than PFBS for all 
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three human OATPs, correlating with the much longer serum elimination half-
lives of PFHxS and PFOS. Thus in addition to hNTCP, hOATP1B1, hOATP1B3 
and hOATP2B1 can contribute to the enterohepatic circulation of PFHxS and 
PFOS and seem to contribute much less to the enterohepatic circulation of PFBS.    
 
Human OATP2B1 is expressed in hepatocytes (Prasad et al., 2014; Peng et al., 
2015), and also at the apical membrane of human enterocytes (Drozdzik et al., 
2014). It can mediate the uptake of steroid hormones, drugs, and other 
xenobiotics (Roth et al., 2012) and hence facilitate their enterohepatic circulation. 
Our findings that hOATP2B1 can transport all three PFSAs suggest that, in 
addition to the previously reported hASBT (Zhao et al., 2015a), hOATP2B1 also 
mediates the uptake of PFOS into enterocytes and thus contributes to the 
enterohepatic circulation of PFOS. Furthermore, since hASBT cannot transport 
PFHxS (Zhao et al., 2015a), hOATP2B1 is the first human transporter expressed 
in the intestine that is reported to mediate the reabsorption of PFHxS.  
 
In addition to these human liver OATPs, we also identified three OATPs 
expressed in rat livers, rOATP1A1, rOATP1B2, and rOATP2B1, that are able to 
mediate the uptake of PFBS, PFHxS and PFOS. Rat OATP1A1 transported 
PFHxS with a similar affinity (Km = 256 µM) as rNTCP (Km = 294 µM). Its affinity 
to PFOS (Km = 37 µM) was much higher and close to the affinities of the human 
liver OATPs. Rat OATP1A1 is also expressed in the apical membrane of renal 
proximal tubular epithelial cells (Bergwerk et al., 1996b), where it can mediate 
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the reabsorption of organic anions in exchange for intracellular reduced 
glutathione (Li et al., 1998). In addition, rOATP1A1 is expressed in a male-
dominant manner (Kato et al., 2002). We previously demonstrated that 
rOATP1A1 transports several PFCAs, such as PFOA, and hence, at least partly, 
contributes to the longer serum elimination half-life of PFOA in male rats (Weaver 
et al., 2010). As for PFHxS, pharmacokinetic studies revealed that the elimination 
half-life is much slower in male rats (T1/2 = 29.1 days) than in female rats (T1/2 = 
1.6 days) (Sundstrom et al., 2012). Increased reabsorption of PFHxS in male rats 
via rOATP1A1 could be part of the mechanism for this gender-specific difference 
in elimination. Although rOATP1A1 can also transport PFOS, the elimination half-
life of PFOS in male rats is somewhat shorter than in female rats (Chang et al., 
2012), indicating that rOATP1A1 is not the major transporter for the renal 
elimination of PFOS.  
 
Enterohepatic circulation of PFOS was not only observed in humans, but also in 
rats (Johnson et al., 1984). So far the mechanism for intestinal reabsorption of 
PFOS, and also of PFBS and PFHxS, in rats could not be explained because, 
unlike in humans, rASBT does not transport these PFSAs (Zhao et al., 2015a). In 
the present study we report, for the first time, that rOATP1A5 and rOATP2B1, 
OATPs expressed in rat intestine, transport all three PFSAs. Thus, reabsorption 
of PFOS via rOATP1A5 and rOATP2B1 offers an explanation as to how PFOS 
can be kept in the enterohepatic circulation in the absence of rASBT-mediated 
transport.   
	  104	  
Differential renal clearance was observed for PFCA and PFSA analogs with 
different chain-lengths according to pharmacokinetic studies in animal models 
(Olsen et al., 2009; Chang et al., 2012; Han et al., 2012; Sundstrom et al., 2012). 
The transport of PFSAs was also chain-length dependent. As we discussed 
previously, NTCP transported PFSAs with decreasing affinity but increasing 
capacity as the chain-length increased. The opposite trend was seen for OATP-
mediated uptake. For all five of the OATPs where kinetic analysis was possible, 
PFOS was transported with the highest affinity, followed by PFBS and PFHxS 
which were transported with similar but clearly lower affinities. Nevertheless, 
transport efficiency generally increased with the increase in chain-length because 
Vmax values were always higher for PFHxS and PFOS. As indicated before, this 
higher transport efficiency could well be, at least in part, the distinguishing 
mechanism for the much shorter half-life of PFBS compared to the longer half-
lives of PFHxS and PFOS.  
 
We have previously shown that rOATP1A1 can transport the perfluoroalkyl 
carboxylates C7 to C10 (Weaver et al., 2010) and contributes to the gender-
specific renal elimination of C8 to C10. Given that rOATP1A1 is also expressed 
in the liver, we tested in the current study whether any of the OATPs expressed 
in human hepatocytes would transport these carboxylates and thus could 
contribute to the long half-lives of these chemicals (Olsen et al., 2007) by helping 
to keep them within the enterohepatic circulation in humans. The fact that all 
three OATPs expressed in human hepatocytes can transport all or some of the 
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four PFCAs, and that the two major liver OATPs, hOATP1B1 and hOATP1B3, 
transport the longer chain C8 to C10 better than the shorter C7 support a 
potential role of these OATPs in the longer serum elimination half-lives of these 
PFCAs.   
 
In conclusion, our studies demonstrate that PFBS, PFHxS and PFOS are 
substrates of several OATPs (hOATP1B1, hOATP1B3, hOATP2B1, rOATP1A1, 
rOATP1B2, rOATP2B1 and rOATP1A5) expressed in hepatocytes and 
enterocytes in humans and rats. Furthermore, PFCAs with 7 to 10 carbons are 
substrates of hOATP1B1.  In addition, hOATP1B3 transports at least C8 and C10, 
and hOATP2B1 transports C8. Thus, the sodium-independent transporters of the 
OATP family serve as additional mediators to facilitate the enterohepatic 
circulation of PFHxS and PFOS in humans and rats and rOATP1A1 might 














Xenobiotics with molecular weight higher than 450 Da tend to enter the liver and 
undergo biliary excretion. In contrast, xenobiotics with molecular weight lower 
than 350 Da are more likely to be eliminated through urine (Hirom, 1976). 
Pharmacokinetic studies in laboratory animals revealed that PFASs with long 
chain-length (PFOS; C8; 500 Da) are excreted through feces, with short chain-
length (PFBS; C4; 300 Da) through urine and with intermediate chain-length 
(PFHxS; C6; 400 Da) through both routes (Olsen et al., 2009; Chang et al., 2012; 
Sundstrom et al., 2012). 
 
Glomerular filtration and tubular secretion in the kidney are the major 
mechanisms involved in the excretion of water-soluble undesired endogenous 
metabolites and exogenous compounds, while tubular reabsorption prevents the 
loss of useful solutes and metabolites. With respect to tubular secretion and 
reabsorption of organic anions, transporters expressed in the proximal tubules 
play an important role. Transporter families involved in the transport of organic 
anions in the kidney include the organic anion transporter (OAT) family, the 
organic anion transporting polypeptide (OATP) superfamily, and the multidrug 
resistance associated protein (MRP) superfamilies (Sekine et al., 2006; You and 
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Morris, 2007). Members of all these families are multispecific transporters that 
mediate the transport of a broad range of structurally diverse compounds and 
have overlapping substrate specificities within the families (Roth et al., 2012). 
Proximal tubular epithelial cells are polarized epithelial cells with the basolateral 
membrane facing the blood and the apical membrane facing the tubular lumen. 



















                                 
Figure 5-1: Transporters for organic anions expressed in proximal tubular 
epithelial cells of rat kidney 
At the apical membrane of proximal tubules of rat kidney, OATP1A1 (Bergwerk et 
al., 1996a), OATP1A3 (Masuda et al., 1997; Masuda et al., 1999), OAT2 (Kojima 
et al., 2002), OAT5 (Anzai et al., 2005), and URAT1 (Rizwan and Burckhardt, 
2007) are uptake transporters mediating the reabsorption of organic anions from 
the urine while MRP2 (Schaub et al., 1999) and MRP4 (van Aubel et al., 2002) 
are responsible for secretion. Additional uptake transporters including OAT1, 
OAT3 (Tojo et al., 1999; Kojima et al., 2002) and OATP4C1 (Kuo et al., 2012) 
expressed at the basolateral membrane are also involved in the secretion of 















Transporters expressed in the kidney and regulated by sex hormones play a role 
in the gender-dependent clearance of PFASs (Kudo et al., 2002). Several human 
and rat transporters mediate the uptake of PFCAs in vitro. PFOA is a substrate of 
renal uptake transporters, including human and rat OAT1, OAT3, URAT1, human 
OAT4, as well as rat OAT2 and OATP1A1 (Katakura et al., 2007b; Nakagawa et 
al., 2008; Weaver et al., 2010; Yang et al., 2010). In addition to PFOA, our group 
showed that rat OAT1, OAT3 and OATP1A1 could also transport PFCA with 7, 9 
and 10 carbons (Weaver et al., 2010). Although not absolutely conclusive, 
OATP1A1 seems to be the major contributor to the gender-dependent renal 
elimination of PFCAs in rats because its higher expression levels in males would 
allow OATP1A1, which is expressed at the apical membrane to reabsorb more 
filtered and secreted PFCAs than in females. We and others also reported that 
inhibition of the model substrate uptake by these transporters is chain length-
dependent, suggesting a role of transporters in the chain length-dependent 
clearance (Weaver et al., 2010; Yang et al., 2010). Given that the expression of 
specific transporters differs among species, it is reasonable to speculate that 
transporter studies will explain the species differences in the renal clearance of 
PFSAs. 
  
To determine whether any of the OATs expressed in the proximal tubular 
basolateral membrane are involved in the renal secretion of PFSAs in rats, we 
measured the transport of PFBS, PFHxS and PFOS by rOAT1 and rOAT3 
transiently expressed in HEK293 cells. We found that PFBS and PFHxS are 
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substrates of both rOAT1 and rOAT3. Based on these results, further kinetic 
characterizations were performed. 
 
II. Results 
2.1 Uptake of PFSAs by rat OAT1 and OAT3 
To determine whether PFSAs are substrates of the rat kidney transporters rOAT1 
and rOAT3, uptake of 10 µM PFBS, PFHxS and PFOS was measured at 1 min 
using HEK293 cells transiently expressing rOAT1 or rOAT3. As shown in Fig 5-2, 
rat OAT1 and OAT3 transport PFBS and PFHxS, but not PFOS. Net uptake of 
PFHxS was higher than uptake of PFBS while the signal-to-noise ratio was 
greater for PFBS. Rat OAT3 mediated uptake had a slightly higher signal than 









Figure 5-2: Uptake of PFSAs by rOAT1 (A) and rOAT3 (B) 
HEK293 cells transiently transfected with empty vector pExpress-1(EV, white 
bars) and rOAT1 or rOAT3 (grey bars) were used to measure the uptake of 10 
µM PFBS, PFHxS, and PFOS for 1 min at 37°C. Net uptake (black bars) was 
calculated by subtracting the values of uptake mediated by EV transfected cells 
from uptake mediated by transporter transfected cells. Each bar represents the 
mean ± SD from two independent experiments each performed with triplicate 

























































2.2 Kinetic determinations of PFBS and PFHxS by rat OAT1 and OAT3 
To further characterize the transport by rOAT1 and rOAT3, time-dependent 
uptake of PFBS and PFHxS at low (10 µM) and high (400 µM) substrate 
concentration was measured. At low substrate concentration, the uptake by 
rOAT1 was linear up to 1 min for PFBS and to 30 sec for PFHxS (Fig 5-3A and 5-
3B). Rat OAT3 mediated uptake of PFBS and PFHxS was linear up to 1 min and 
2 min, respectively (Fig 5-3C and 5-3D). At high substrate concentrations, uptake 
for both substrates by both transporters was linear up to 30 sec (data not shown).  
 
To stay within the initial linear range, concentration-dependent uptake of PFBS 
and PFHxS by rOAT1 and rOAT3 was measured at 20 sec. As can be seen in 
Fig 5-4, uptake was saturable. The kinetic parameters were calculated based on 
the Michaelis-Menten equation and are summarized in Table 5-1. The transport 
of PFBS mediated by rOAT1 has the lowest affinity (Km=285 µM) and slowest 
intrinsic clearance (Vmax/Km=9.8 µl/mg protein*min-1). Transport of PFHxS by 
rOAT1 (Km=72.7 µM, Vmax=4.1 nmol/mg protein*min-1) has highest capacity with 
similar affinity as transport of PFBS (Km=57.0 µM) and PFHxS (Km=48.5 µM) by 
rOAT3. Both rOAT1 and rOAT3 transport PFHxS with greater affinity and higher 







Figure 5-3: Time-dependent uptake of PFSAs by rOAT1 (A, B) and rOAT3 
(C, D) 
Uptake of 10 µM PFBS (A, C) and PFHxS (B, D) was measured at 37°C at the 
indicated time points using HEK293 cells transiently transfected with EV (circles), 
rOAT1 or rOAT3 (squares). Net uptake (triangles) was calculated by subtracting 
the value of uptake mediated by EV transfected cells from uptake mediated by 
transporter transfected cells. The results were corrected for total protein 



















































































Figure 5-4: Kinetics of rOAT1- (A, B) and rOAT3- (C, D) mediated transport 
of PFBS (A, C) and PFHxS (B, D) 
HEK293 cells transiently transfected with EV, rOAT1 or rOAT3 were used to 
measure the uptake of increasing concentrations of PFBS and PFHxS. Net 
uptake was calculated by subtracting the values of uptake mediated by EV 
transfected cells from uptake mediated by transporter transfected cells. Resulting 
data were fitted to the Michaelis-Menten equation to obtain Km and Vmax values 
(Table 5-1). The results were corrected for total protein concentration in each 
well. Each point represents the mean ± SD from three to four independent 





















































































Table 5-1: Kinetic parameters of PFBS and PFHxS transport mediated by 
rat OAT1 and OAT3 





PFBS 285±60 2.8±0.3 9.8 
PFHxS 73±29 4.1±0.7 56 
rOAT3 
PFBS 57±17 1.6±0.2 28 















In this chapter, we have demonstrated that rOAT1 and rOAT3 can transport 
PFBS and PFHxS, and determined the kinetic parameters of the transport.  
Our results might help to explain the differences of elimination half-lives among 
PFSAs with different chain-lengths. Active secretion mediated by rOAT1 and 
rOAT3 of PFBS together with its relatively low molecular weight might contribute, 
at least in part, to the fast elimination in rats. The high molecular weight and 
serum protein binding prevent efficient glomerular filtration of PFHxS and PFOS. 
However, a small portion of PFHxS is excreted via urine, possibly due to the 
transport by rOAT1 and rOAT3. In the previous chapters, our results indicated 
that the liver transporters NTCP and OATPs are responsible for the uptake of 
PFBS, PFHxS and PFOS into hepatocytes. In general, PFOS and PFHxS were 
transported with higher efficiency than of PFBS, suggesting a greater probability 
for PFOS and PFHxS to accumulate in human and rat liver. 
 
Our group characterized the transport of PFCAs with 7 and 8 carbons (C7 and 
C8) by rOAT1 and PFCAs with 8 and 9 carbons (C8 and C9) by rOAT3 in 2010 
(Weaver et al., 2010). Compared to the transport of C7 (Km=51 µM, Vmax=2.2 
nmol/mg protein*min-1) and C8 (Km=43 µM, Vmax=2.6 nmol/mg protein*min-1) by 
rOAT1, the transport of PFHxS (Km=73 µM, Vmax=4.1 nmol/mg protein*min-1) has 
lower affinity but higher capacity, leading to a comparable overall intrinsic 
clearance.  
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The affinity of PFBS (Km=57.0 µM for C8) and PFHxS (Km=49 µM) transport is 
similar as for C8 (Km=66 µM) transport by rOAT3 while the capacity is lower than 
the transport of both C8 (Vmax=3.8 nmol/mg protein*min-1) and C9 (Vmax=8.7 
nmol/mg protein*min-1). Overall, for the transport by rOAT1 and rOAT3, PFHxS 
which corresponds in terms of carbon atoms to C7 and C8 have very similar 
characteristics. 
  
In conclusion, our studies reveal that PFBS and PFHxS are substrates of rOAT1 
and rOAT3, contributing to their relatively shorter elimination half-lives compared 
















Summary and overall discussion 
The strong carbon-fluorine bonds of perfluoroalkyl substances (PFASs) make 
them excellent surfactants, but on the other hand, very resistant to environmental 
degradation. Consequently, once released into the environment, certain PFASs, 
including PFOA and PFOS, are very persistent and can be transported all around 
the world, even to the Arctic regions (Shoeib et al., 2006; Butt et al., 2010). 
PFOA and PFOS are detected in almost all the human blood samples being 
tested (Lau et al., 2007; Centers for Disease Control and Prevention, 2015). 
PFASs were also found in other human specimens, including umbilical cord 
blood (Apelberg et al., 2007), breast milk (Tao et al., 2008a; Tao et al., 2008b; 
Crinnion, 2010) and organs like liver, kidney and lung (Karrman et al., 2010; 
Perez et al., 2013). Based on epidemiological data obtained from retired workers, 
PFOA, PFHxS and PFOS have very long half-lives in humans (Olsen et al., 
2007). Due to their wide distribution and extreme persistence, numerous studies 
focused on the toxicities and pharmacokinetics of PFOA and PFOS. However, a 
clear knowledge gap exists to explain the molecular mechanisms responsible for 
the long half-lives of PFOA, PFHxS and PFOS. 
 
It was speculated that transporters as well as serum protein binding could 
contribute to the long elimination half-lives of PFOA and PFOS. Following this 
hypothesis, several studies regarding interactions between different serum 
proteins and PFOA and/or PFOS were conducted. The majority of the studies 
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dealt with interactions between PFOA and/or PFOS and serum albumin (Jones et 
al., 2003; Chen and Guo, 2009; Zhang et al., 2009; Salvalaglio et al., 2010; Luo 
et al., 2012; Beesoon and Martin, 2015; Wang et al., 2016a). In addition, PFOS 
and PFOA could also interact with hemoglobin, fatty-acid binding proteins as well 
as transthyretin-bound thyroxin in plasma (Luebker et al., 2002; Audet-Delage et 
al., 2013; Wang et al., 2016b). Furthermore, fluorescence displacement studies 
indicated that also the shorter chain length PFBS and PFBA could interact with 
human serum albumin (Chen and Guo, 2009). With respect to the role of 
membrane transport proteins in the pharmacokinetics of PFASs, previous studies 
mainly focused on PFCAs and kidney transporters. Weaver et al. and Yang et al. 
demonstrated that OATP1A1, which is expressed at higher levels in male rats, 
transports PFOA, potentially explaining the gender-dependent excretion of PFOA 
in rats (Yang et al., 2009; Weaver et al., 2010). In humans, OAT4 expressed at 
the apical membrane of proximal tubular epithelial cells mediates the 
reabsorption of PFOA from urine and therefore increases its elimination half-life 
(Yang et al., 2010). In contrast, little was known regarding the interaction of 
PFSAs and liver or intestinal transporters prior to this dissertation. Although Han 
et al. showed that active transport was involved in the uptake of PFOA into 
freshly isolated rat hepatocytes (Han et al., 2008), no specific transporter was 
previously identified.  
 
In Chapters 3 and 4, I evaluated the hypothesis that liver and intestinal 
transporters involved in the enterohepatic circulation of bile acids contribute to 
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the long half-lives of PFHxS and PFOS in rats and humans. Because of the 
discontinuous sinusoidal capillaries present in the liver, even large molecules like 
serum proteins in the circulation can enter the perisinusoidal space surrounding 
the hepatocytes. This allows both unbound and bound PFSAs to access the 
space of Disse and to interact with transporters in the hepatocytes. The uptake 
system for organic solutes consists of sodium-dependent and sodium-
independent transporters at the sinusoidal membrane of hepatocytes. Using cells 
overexpressing several of these different transporters, I demonstrated that both 
sodium-dependent and sodium-independent uptake transporters could mediate 
the transport of PFBS, PFHxS and PFOS in humans and rats. These 
transporters include human and rat NTCP, human OATP1B1, OATP1B3, 
OATP2B1, and rat OATP1A1, OATP1B2, and OATP2B1. Within the hepatocytes, 
PFOA and PFOS might bind to and be transported across the cell by fatty acid 
binding proteins (Luebker et al., 2002). My inhibition results obtained with Sf9 
vesicles, shown in Chapter 3, suggest that after reaching the canalicular 
membrane, the human ABC transporters MRP2 and BCRP seem to be involved 
in the efflux of PFHxS while BSEP and MRP2 might handle PFOS. Along with 
bile, PFHxS and PFOS are released into the intestine after a meal. Transporters 
located at the brush border membrane of enterocytes could then reabsorb 
PFHxS and PFOS. In particular, I demonstrated that human ASBT mediates the 
influx of PFOS in a sodium-dependent manner. In contrast, PFBS, PFHxS and 
PFOS are substrates of human OATP2B1 and rat OATP1A5, indicating that 
these transporters play a role in the sodium-independent reabsorption of these 
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compounds from the intestine. Furthermore, I have also shown that OSTα-OSTβ 
transports PFBS, PFHxS and PFOS, suggesting a role for this heterodimeric 
transporter in the reabsorption of these compounds and their transport back into 
the blood stream. With the assistance of all these transporters, PFHxS and 
PFOS are retained in the body within the enterohepatic circulation for a long time, 
which is evidenced by the studies that showed that cholestyramine enhanced 
their fecal excretion (Johnson et al., 1984; Genuis et al., 2013).  
 
In comparison with OATPs expressed in hepatocytes, the sodium dependent 
transporter NTCP is the dominant mediator for PFSAs transport, indicated by the 
hepatocyte uptake studies in Chapter 3. BSP inhibited both the sodium 
dependent and independent uptake of PFBS and PFHxS into human and rat 
hepatocytes. The fact that the BSP-inhibitable sodium independent uptake, which 
is the combination of the contribution of all OATPs, only constituted a minor 
portion of the total inhibition, suggests a major role of the sodium dependent 
transporter NTCP under the experimental conditions I used. The results 
regarding specific transporters in Chapter 3 and Chapter 4 are in good 
agreement with the uptake measurement obtained with isolated hepatocytes. 
Generally, in humans, the transport of the three PFSAs by OATPs has similar or 
even higher affinity compared to NTCP mediated transport. However, the 
capacity of PFSAs transport by NTCP (Vmax=3.7 nmol/mg protein*min-1 for PFBS; 
23.2nmol/mg protein*min-1 for PFHxS; 30.7 nmol/mg protein*min-1 for PFOS) is 
considerably higher than the one mediated by OATPs (Vmax=0.2 to 0.6 nmol/mg 
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protein*min-1 for PFBS; 2.0 to 2.4 nmol/mg protein*min-1 for PFHxS; 0.8 to 4.7 
nmol/mg protein*min-1 for PFOS). Taken together, NTCP-mediated uptake has a 
range of intrinsic clearance (Vmax/Km) of 100 to 200 µl/mg protein*min-1, which is 
significantly higher than OATP-mediated transport. Regarding rat liver uptake 
transporters, I could not perform kinetic determinations for rat OATP1B2 and 
OATP2B1, as well as for PFOS transport by rat NTCP, due to the low signal-to-
noise ratios. But the kinetic parameters for rat OATP1A1-mediated transport of 
PFHxS and PFOS, and rat NTCP-mediated transport of PFBS and PFHxS were 
determined. The affinities of rOATP1A1 and rNTCP were similar while rNTCP 
mediated uptake has a much higher capacity (Vmax=8.1 nmol/mg protein*min-1 for 
rNTCP; 1.0 nmol/mg protein*min-1 for rOATP1A1). Collectively, the results of the 
hepatocyte uptake determinations as well as cell-based uptake studies for 
specific transporters indicate that NTCP plays a more important role than OATPs 
in mediating the influx of PFSAs into the liver. 
 
Although OATPs are not the major players, it is still worth noticing that they are 
able to transport PFHxS and PFOS better than PFBS in humans and rats. The 
affinity of PFBS transport by OATPs is generally similar or a little bit lower than 
PFHxS and PFOS transport. However, the capacity of PFBS transport is much 
lower (Vmax=0.2 nmol/mg protein*min-1 for human OATP1B1, OATP1B3 and rat 
OATP1A5; 0.6 nmol/mg protein*min-1 for human OATP2B1). As two liver-specific 
transporters, human OATP1B1 and OATP1B3 are frequently compared with 
each other with respect to substrate specificities. These two transporters share 
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many substrates, including estradiol-17β-glucuronide, BSP and several statins 
(Roth et al., 2012). However, they also have their specific substrates. For 
example, cholecystokinin octapeptide (CCK-8) is a substrate for OATP1B3 but 
not for OATP1B1 while estrone-3-sulfate at low concentrations is not transported 
by OATP1B3 (Hirano et al., 2004). When it comes to the transport of PFSAs, 
OATP1B1 and OATP1B3 behave very similarly for all three substrates in terms of 
affinity and capacity, as summarized in Table 4-3. Human OATP2B1 is not 
selectively expressed in the liver. A recent meta-analysis demonstrated that the 
expression level of OATP2B1 is close to OATP1B3 but lower than OATP1B1 in 
human liver (Badee et al., 2015). Table 4-3 shows that OATP2B1 transports 
PFBS and PFHxS similarly as OATP1B1 and OATP1B3 but it transports PFOS a 
little better than the other two transporters, indicated by the higher Vmax value. In 
addition to PFSAs transport, uptake measurement of PFCAs with 7 to 10 carbons 
by human OATPs were also performed at one concentration and at one single 
time point. As PFOS (a C8 PFSA), PFOA (a C8 PFCA) is also a substrate for all 
the human liver OATPs. However, since we were not able to perform kinetic 
determinations, it is not feasible to compare PFOA and PFOS transport in detail. 
 
PFBS, with only four carbon atoms, does not belong to the long chain PFSAs 
and is not as widely distributed as PFHxS and PFOS, possibly due to lower 
industrial production. However, it would be beneficial if we could understand the 
influence of transporters on the pharmacokinetics of PFBS because it has 
become one of the substitutes developed to replace PFOS. As PFHxS and 
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PFOS, PFBS is also a substrate of several transporters examined in the 
dissertation, including NTCP and all the OATPs. In addition, in Chapter 5, I 
demonstrated that rOAT1 and rOAT3 expressed at the apical membrane of 
proximal tubular epithelial cells mediates the transport of PFBS and PFHxS. 
Nevertheless, the estimated elimination half-life of PFBS (26 days in humans and 
3.9-4.5 days in rats) is much shorter than the ones for PFHxS and PFOS and 
neither enterohepatic circulation nor liver accumulation have been reported for 
PFBS in humans or laboratory animals. By comparing the transport properties of 
PFBS to PFHxS and PFOS, we can explain the shorter half-life to some extent.  
Firstly, PFHxS and PFOS are better substrates of liver transporters NTCP and 
OATPs, indicated by the higher intrinsic clearance (Vmax/Km) listed in Table 3-2 
and 4-3. Secondly, no inhibition of any efflux transporters by PFBS was seen, 
indicating that PFBS might not get into the enterohepatic circulation because it 
lacks a way out of hepatocytes into the bile ducts. Thirdly, although I showed that 
rOATP1A5 in the intestine can mediate the uptake of PFBS, its capacity to 
transport PFBS is much lower than the capacity for PFHxS and PFOS. So even if 
a small amount of PFBS reaches the intestine along with bile, it is likely to 
escape reabsorption. Last but not least, as we mentioned in Chapter 5, the 
smaller molecular size allows the majority of the dose of PFBS to undergo 
glomerular filtration in the kidney. With respect to transporters expressed in the 
proximal tubule, I have shown that rOATP1A1 is not a good transporter for PFBS 
while the transport by rOAT1 and rOAT3 is much better. Because of the 
potentially greater secretion than reabsorption, I conclude that PFBS is excreted 
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readily in urine, which can explain the much shorter elimination half-life in rats. In 
humans, PFBS is excreted faster than PFHxS and PFOS, but the half-life is still 
significantly longer than in rats. To address the mechanisms for the species 
difference, additional tests are needed. For instance, it is not known whether 
PFBS is a substrate of hOAT4, which could influence its renal excretion since the 
transporter is expressed at the apical membrane and mediates the reabsorption 
of organic anions in the proximal tubule in humans. 
 
Among all the transporters tested, only OATP1B1 and OATP1B3 are selectively 
expressed in human liver. The other transporters are expressed in additional 
cells beside hepatocytes and/or enterocytes. In addition to the enterohepatic 
circulation, ASBT expressed at the apical membrane of bile duct epithelial cells 
also participates in the formation of the intrahepatic circulation. As a substrate of 
human ASBT, PFOS might get trapped within the liver via this intrahepatic 
circulation. OATP2B1, which can mediate the influx of PFOS, is also located at 
the blood brain barrier (BBB) and blood placenta barrier (Roth et al., 2012). 
However, unlike in the liver, the concentration of PFOS in cerebrospinal fluid is 
considerably lower than in serum and no accumulation has been seen (Harada et 
al., 2007). The underlying mechanism might include binding of PFOS to plasma 
membrane proteins to prevent it from crossing the tight BBB. Besides this, there 
might be efflux pumps like MRP3 located at the BBB that mediate the extrusion 
of PFOS, which have not been tested yet (Zhao et al., 2015b). Furthermore, as I 
mentioned before, PFOS is found in umbilical cord blood, suggesting potential 
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placental transfer in humans. The involvement of transporters in mediating the 
maternal to fetal transport has not been reported so far. However, there is 
evidence showing that human OAT4, expressed at the fetal side of the epithelium, 
might reduce the placental passage of PFOS and PFOA (Yang et al., 2010; 
Kummu et al., 2015). Like OAT4, OATP2B1 is also expressed at the fetal side in 
the placenta, suggesting it might also play a role in decreasing the placental 
transfer of PFOS.  
 
As shown in Chapters 3 to 5, the background uptake increases as the chain-
length increases.  One reason could be non-specific binding to the membrane 
due to increased lipophilicity. To assay this, vesicles made from CHO or HEK293 
cells could be used to confirm whether the chemicals get into cells or stay in the 
membrane. Another possibility for the high background is the expression of other 
so far not identified transporters, which can transport PFOS, in these cell lines.  
 
Until now, studies of PFASs in humans have been mainly focused on plasma 
concentrations. However, the knowledge on the burden of PFASs in other human 
compartments is also important for monitoring as well as for health risk 
assessment. A physiologically based pharmacokinetic (PBPK) model in monkeys 
for PFASs was first generated to fill in this knowledge gap (Andersen et al., 2006). 
The authors claimed that capacity-limited, saturable processes must be involved 
in the kinetic behavior of PFOA and PFOS because they found that the apparent 
elimination rates differ with increasing dose. Therefore, renal reabsorption by 
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transporters should be considered. Later, another group included renal 
absorption for PFOA and PFOS to their PBPK model in humans and rats, and 
was able to successfully simulate the data collected from residents of two 
communities exposed to PFOA in drinking water (Loccisano et al., 2011; 
Loccisano et al., 2012). Kinetic parameters of PFOA transport by OATP1A1 
calculated by Yang, et al. (Yang et al., 2009) were used in the rat PBPK model. 
In these models, uptake of PFOA and PFOS into the liver was considered a 
simple diffusion process. However, my findings suggest that it is a saturable 
process, suggesting the involvement of carrier-mediated transport. Thus, it is 
reasonable to speculate that the results in my dissertation could help to improve 
the PBPK model in rats and humans, especially for the liver compartment. 
 
Overall, in this dissertation, I examined the interactions of PFASs with membrane 
transport proteins, focusing on the liver, intestine and kidney. First of all, I 
demonstrated that the uptake of PFBS, PFHxS and PFOS into freshly isolated 
human and rat hepatocytes involves active transport. Based on this result, I 
found that transporters expressed within the enterohepatic circulation mediate 
the transport of PFBS, PFHxS and/or PFOS. In the liver, human and rat NTCP, 
human OATP1B1, OATP1B3, OATP2B1 and rat OATP1A1, OATP1B2, 
OATP2B1 can mediate the transport of all three PFSAs. At the canalicular 
membrane of human hepatocytes, PFHxS and PFOS inhibited efflux transporters 
for organic anions. In the intestine, I showed that human ASBT can mediate the 
reabsorption of PFOS while all three PFSAs are substrates of human OATP2B1 
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and rat OATP1A5. Human OSTα-OSTβ, which mediates the influx and efflux of 
substrates along their concentration gradients, could transport PFBS, PFHxS and 
PFOS. In addition, I found that rat OAT1 and rat OAT3 expressed in the rat 
kidney can transport PFBS and PFHxS and thus could facilitate their renal 
secretion. However, we still need to prove these interactions in vivo and figure 

















The results in this dissertation were all generated based on in vitro systems. How 
to confirm them in vivo becomes a major challenge, not only for the dissertation, 
but also for transport studies in general. Common resources used for uptake 
studies include perfused organs, isolated cells, isolated membrane vesicles, as 
well as cloned specific transporters that are expressed in oocytes or mammalian 
cell lines (Hagenbuch, 2010). Nowadays, cell-based transport assays have 
become very popular because on the one hand, specific transporters can be 
identified and on the other hand, they are more convenient for kinetic 
determinations. Using these methods, many substrates of SLC transporters have 
been identified. In order to prove that the transport really occurs in vivo, specific 
or selective inhibitors of the tested transporters should be used for these 
examinations. Although it is not feasible to perform such tests in humans, using 
freshly isolated hepatocytes is the gold standard alternative for human liver 
studies. However, to the best of our knowledge, selective inhibitors for OATPs or 
NTCP are not yet available. Even if we could find such inhibitors, the results 
might not allow to make final conclusions because of the redundancy of several 
transporters for one compound in the same membrane. For example, selective 
inhibitors of ASBT, such as A4250 (Baghdasaryan et al., 2016), were developed 
because of their potential therapeutic effect. However, even when ASBT is 
inhibited, OATP2B1 in the intestine can still mediate the reabsorption of PFOS in 
humans. Therefore, the lack of selective inhibitors for these human transporters 
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together with the redundancy of several transporters for one substrate makes it 
difficult to address the in vivo situation. Besides human transporters, rat 
transporters were also included in the dissertation and in many other studies. As 
for human transporters, no specific inhibitors are available for the rat transporters. 
Knockout rats for any of these transporters are not available so far. However, 
with the development of zinc finger nuclease technology (Geurts et al., 2009) and 
the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas 
system (Shao et al., 2014), it should be possible to obtain knockout rats for these 
transporters. However, again, due to the fact of several transporters for one 
substrate, single gene knockout animals can easily lead to redundancy and 
compensation. One potential solution is to generate conditional double knockout 
rats with inactivated NTCP-and OATP1A/1B, for instance, in the liver, to confirm 
their roles in vivo. Although Oatp1a/1b-knockout mice are available (van de 
Steeg et al., 2010), transport of PFASs by mouse transporters has not been 
determined yet. Given the similarity of transporting properties between mouse 
and rat transporters, we might speculate that the same mouse transporters are 
involved in the disposition of PFASs as in rats. However, compensation by NTCP 
in the liver and ASBT in the intestine might still exist.  
 
To better address the mechanisms for the long half-lives of PFOA and PFOS 
with respect to drug transporters, it is also important to study the efflux 
transporters. In this dissertation, I only conducted inhibition studies for the three 
human efflux transporters BSEP, BCRP and MRP2, using Sf9 vesicles. However, 
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direct transport measurements are needed since inhibition does not necessarily 
mean that the inhibitors are also substrates. Several methods could be adopted 
in order to determine direct transport in the future. For instance, sandwich 
cultured hepatocytes are a powerful tool to measure hepatobiliary drug transport 
(Swift et al., 2010). Biliary efflux studies could be conducted by including steps to 
preload the cells, disrupt the tight junctions and then incubate the cells with their 
respective buffers as described earlier (Liu et al., 1999). Although this method is 
suitable to demonstrate biliary transport, specific transporters cannot be 
distinguished. By expressing a pair of uptake and efflux transporters in a 
polarized cell line, like the Madin-Darby canine kidney (MDCK) cells or the 
porcine kidney LLC-PK1 cells, vectorial transport could be measured to identify a 
substrate of either the uptake or the efflux transporters. If we use this method for 
PFSAs, NTCP could be expressed at the basolateral membrane as an influx 
mediator and at the apical membrane, the efflux transporter of interest 
(BSEP/BCRP/MRP2) could be expressed. In this way, a compound could be 
tested by measuring trans-cellular transport. 
 
This dissertation focused on PFSAs transport by liver and intestinal transporters. 
With respect to kidney transporters, I determined the transport of PFBS, PFHxS 
and PFOS by rat OAT1, OAT3 and OATP1A1, which are also transporters for 
PFCAs. Nevertheless, it is still important to examine the human kidney 
transporters for PFSAs because renal reabsorption could contribute to the long 
half-life of a compound. Human OAT4 and URAT1 were shown to transport 
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PFOA. Since PFOS is structurally very similar to PFOA, these two transporters 
are good candidates to be tested in the future. 
 
Given that PFOS and PFHxS excretion is enhanced by cholestyramine treatment 
PFOA might also undergo enterohepatic circulation in rats and humans (Johnson 
et al., 1984; Genuis et al., 2013). However, previous studies of PFOA have 
focused only on kidney transporters. Sodium-dependent transport of PFSAs was 
first reported in my dissertation and NTCP seems to transport PFSAs better than 
OATPs. In the future, it would be interesting to test whether the same 
transporters that are involved in the enterohepatic circulation of PFSAs are also 
involved in the enterohepatic circulation of PFOA, especially the sodium 
dependent transporters NTCP and ASBT.  
 
All the experiments and strategies mentioned above will lead to a better 
understanding of the molecular mechanisms of the long half-lives of long-chain 
PFASs in humans and should allow to improve existing PBPK models that can 
be used to predict the disposition of these environmentally persistent compounds. 
Furthermore, this work will help to identify individuals who might be susceptible to 
the potential adverse effects of PFASs. For instance, occupational workers with 
OATP1B1/OATP1B3 polymorphisms that result in high transporter expression 
could have much higher concentrations of these compounds in the hepatocytes 
and potentially lead to liver diseases, such as hepatomegaly, steatosis, and 
hepatocellular carcinoma via activation of HNF4α.  
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